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ABSTRACT 
Background 
Aerosol therapy is an important and frequently used method of delivering drugs to the patient on 
mechanical ventilation (MV).  Different types of aerosol devices are available to deliver drug therapy 
during MV.  These devices need to be used according to the manufacturer’s guidelines which include 
methods for decontamination and application.  The methods used to store these nebulisers and the 
pathogens in the surrounding air may contribute to the contamination of these devices.  Nebulisers 
have been identified as a possible source of ventilator-associated pneumonia (VAP).  The incidence of 
contamination of nebulisers associated with current decontamination and storage protocols will lay the 
foundation for the development of evidence based practice of aerosol therapy in MV.    
 
Objectives  
The aim of this study was to determine the current incidence of contamination of nebulisers used 
within a ventilator circuit and surrounding air in the intensive care units (ICUs) of hospitals in Pretoria 
and to determine the current practice regarding decontamination and storage of these devices.   
Micro-organisms that colonise these contaminated nebulisers and the surrounding air were also 
identified. 
 
Methods  
A cross-sectional observational analytical study was done in seven ICUs in Pretoria whereby 61 
nebulisers and the surrounding air were sampled and assessed. The unit manager of each ICU was 
asked questions to identify the current decontamination and storage protocols for nebulisers used 
within a ventilator circuit.  Swabs were taken from the chambers of nebulisers used within a ventilator 
circuit and streaked on blood agar plates (BAPs).  An air sampler was used to collect air samples from 
the surrounding environment.  The BAPs of nebulisers and air were incubated for possible bacterial 
and fungal contamination.  Species of the most recurrent colonies observed were identified in both air 
and nebuliser samples. 
 
Results 
A total of 61 nebulisers were sampled including 37 Micro Mist nebulisers and 24 Aeroneb nebulisers.  
The incidence of contamination found in the Micro Mist nebulisers were 51.4% (n=19) and the 
Aeroneb nebulisers were 50% (n=12).  Most of the Aeroneb nebulisers in the ventilator circuit were 
wet which resulted in 50% bacterial contamination.  All the ICUs in the hospitals in Pretoria had 
decontamination and storage protocols for the Micro Mist nebuliser.  These protocols differed between 
ICUs and ICUs within the same hospital.  Staff adherence to these protocols was low as the methods 
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observed for storage and decontamination differed from the protocols stated to be used in the ICUs. 
Contamination rate was the least when the Micro Mist nebuliser was rinsed with alcohol and left open 
to the environment.  Micro Mist nebulisers that were taken apart and left to dry under a sterile cloth 
resulted in the most fungal and bacterial contamination.  No contamination was found in Micro Mist 
nebulisers that were used for Bisolvon aerosolisation.  Coagulase-negative Staphylococcus species 
(spp.) was mostly found in air and Aeroneb samples and Enterococcus spp. mostly in the Micro Mist 
nebuliser.  Both of these micro-organisms are common causes of VAP. 
 
Conclusion 
Both types of nebulisers presented with similar rates of contamination.  Although the ICUs in the 
hospitals had decontamination and storage protocols in place, the incidence of contamination in the 
Micro Mist nebulisers was high.  The rate of contamination in the Micro Mist nebulisers can be 
associated with different decontamination and storage protocols.  This is the first study to identify the 
rate of contamination in the Aeroneb nebuliser.  Most of the Aeroneb nebulisers were wet during the 
time of MV which increased the possibility of contamination.  The micro-organisms found in nebulisers 
and air samples harbour pathogens that can cause VAP.   
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CHAPTER 1 
1. INTRODUCTION 
 
1.1 BACKGROUND 
Delivery of aerosolised pharmacologic agents is described as one of the most important 
adjunctive therapies related to patient care, during mechanical ventilation (MV) (Kallet, 2013).  
Nebulisation is the process whereby liquid medications are aerosolised in order to enhance 
their penetration into the lower respiratory tract of patients in need of symptom relief.  A range 
of aerosol devices are used for administration of medication to patients during the period of 
MV.  These devices  include the jet pneumatic nebuliser, vibrating-mesh nebuliser, ultrasonic 
nebuliser and pressurised metered-dose inhaler (pMDI) with spacer (Ari, Areabi, & Fink, 2010).  
The jet nebuliser is mostly used in the ICU followed by the ultrasonic nebuliser and more 
recently vibrating mesh nebulisers (Dhand, 2008; Robinson, Athota, & Branson, 2009). 
 
Inhaled drug therapy is routinely employed by physiotherapists and ICU nursing staff for the 
management of patients receiving MV.  Bronchodilator agents are among the drugs most 
frequently administered in the ICU (Dhand, 2007; Ellis, Van Aswegen, Roos, & Becker, 2013).  
The main bronchodilator agents that are  used in patients receiving MV are beta-adrenergic 
agonists (Dhand, 2008).  Inhaled drug therapy is also implemented for patients who suffer from 
symptoms apart from bronchospasm and include corticosteroids, prostanoids, surfactant, 
mucolytics and antibiotics (Dhand, 2007).  The nebulisation of medication during MV, results in 
rapid localised  and systemic effects with little side-effects (Dolovich & Dhand, 2011). 
 
Ellis et al. (2013) performed a study to determine the incidence of contamination and the 
practice of decontamination of nebulisers used within a ventilator circuit in ICUs in 
Johannesburg, South Africa.  Results showed that nebulisation was mainly done through the 
re-use of single-use jet nebulisers. It has been noted that 93% of all nebulisers assessed were 
not being used in accordance with the manufacturer’s guidelines as they were marked as 
single-use devices.  Ultrasonic nebulisers were the only additional nebuliser devices used for 
nebulisation within a ventilator circuit (Ellis et al., 2013). 
 
More than half of the re-used jet nebulisers (52%) used within a ventilator circuit presented 
with contamination.   Protocols for decontamination and storage were absent in these ICUs 
and healthcare providers’ lack of knowledge regarding the implications of re-using jet 
nebulisers was evident (Ellis et al., 2013). 
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Ellis et al. (2013) reported that physiotherapists and nursing staff in the ICUs stored these jet 
nebulisers after aerosolisation sessions without decontamination. Some nebulisers were stored 
with residual medication and visible secretions within the chambers of these devices. 
Secretions coughed up by patients can drain into the nebuliser chamber during aerosolisation 
or when left in the ventilator circuit after an aerosolisation session. These devices were 
disconnected from the ventilator circuit and stored next to the patient’s bed in a variety of 
methods which included a) stored within a latex glove; b) covered with a sterile drape; c) stored 
within a paper bag and d) open to the environment (Ellis et al., 2013). These practices could 
potentially have contributed to the growth of bacteria in the nebuliser chambers. Eleven 
percent of nebulisers were stored without protective covering, thus open to the air in the ICU.  
It was suggested that this method of storage might also have contributed to contamination due 
to contaminated air and should be investigated (Ellis et al., 2013). 
 
Ventilator-associated pneumonia (VAP) is an infection that occurs 48 hours after intubation 
and represents 86% of pneumonias acquired in ICUs in America (Rotstein et al., 2008).  
Research regarding VAP in South Africa is limited and only two papers relating to nosocomial 
infection in paediatric ICUs have been published in the last 10 years (Morrow et al., 2009).  
Several studies have shown that contaminated nebulisers have been linked to the incidence of 
VAP (Ball et al., 2005; Dhand, 2008).  Contaminated nebulisers are able to deliver pathogens 
deep into the lower respiratory tract and the depth of penetration depends on the particle size 
generated by the aerosol device (Miller, Amin, Palmer, & al, 2003).  Safdar, Crnich & Maki 
(2005) reported that the main sources of epidemic VAP were contaminated respiratory 
equipment and medical aerosols. 
 
Contaminated hospital air and water are environmental reservoirs contributing to Nosocomial 
Pneumonia (Safdar, Crnich & Maki, 2005).  Airborne transmission is well recognized for many 
human pathogens.  Diseases in the air can be transmitted over small and large distances by 
direct/indirect contact or a combination of routes  (Beggs, Noakes, Sleigh, Fletcher, & Siddiqi, 
2003).  The survival of infectious agents in the air depends on environmental factors such as 
temperature, humidity, ultraviolet (UV) light and other pollutants in the atmosphere (Eames et 
al., 2009). 
 
Huang et al. (2013) collected samples of the surrounding air and various surfaces in two ICUs 
to investigate the extent of microbial contamination. It was noted that Pseudomonas 
aeruginosa was the most frequently detected and abundant bacterium in both surface and air 
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samples.  Samples were taken around the bedsides of patients and the surrounding air.  The 
ventilator represented the most heavily contaminated surface location in both total pathogenic 
bacteria colony counts, and frequency of positive detection. The study also indicated that 
bacterial counts after visitation periods were higher (Huang et al., 2013).  Studies investigating 
the correlation between surface-bound microbial contamination and airborne contamination 
remain limited.  There is no information regarding the correlation between micro-organisms 
cultured from contaminated nebulisers and air samples taken from around the patient’s 
bedside.   
 
1.2 PROBLEM STATEMENT 
There is currently no information regarding the type of nebulisers used within ventilator circuits 
or the incidence of contamination of these devices in ICUs in Pretoria, South Africa. There is 
no documentation regarding the current practices of decontamination and storage of nebulisers 
in these ICUs.  Research is limited regarding the possible correlation between organisms 
identified in contaminated nebulisers stored at a patient’s bedside and organisms detected in 
the surrounding air.   
 
1.3 JUSTIFICATION FOR RESEARCH 
Investigation into the contamination and decontamination of nebulisers used within ventilator 
circuits in ICUs of hospitals is a novel area of research in South Africa.  Ellis et al. (2013) were 
the first to report in this field.  Ellis et al. (2013) studied the current practice in decontamination 
of nebulisers used with in a ventilator circuit in the ICUs of hospitals in Johannesburg.  A 
limitation of the study by Ellis et al. (2013) is that they showed bacterial growth in contaminated 
nebulisers but did not identify the bacteria.  They also didn’t collect air samples around 
patients’ bedsides to determine if bacteria in the air contributed to nebuliser contamination. 
This study sets out to determine if similar practice regarding nebuliser use and 
decontamination of nebulisers, as reported by Ellis et al. (2013), will be found in ICUs of 
hospitals in Pretoria.  In addition air sampling was done to investigate its role in contamination 
of nebulisers.  Bacterial colonies, cultured from the air and nebuliser samples at the same 
bedside were identified for possible correlation.  
 
1.4  RESEARCH QUESTIONS 
1.4.1 What is the incidence of nebuliser contamination within a ventilator circuit in the ICUs of 
hospitals in Pretoria, South Africa?     
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1.4.2 What is the current practice regarding decontamination and storage of nebulisers after use in 
ventilator circuits in ICUs of hospitals in Pretoria?       
                  
1.4.3 What is the extent of air borne contamination around the area where these nebulisers are 
being kept? 
 
1.4.4    Is there any correlation between airborne contaminants and bacteria found in nebulisers?      
 
1.5  HYPOTHESIS 
There is a high rate of contamination of nebulisers used within a ventilator circuit in ICUs of 
hospitals in Pretoria, South Africa because nebulisers are not effectively decontaminated after 
being used within a ventilator circuit.   
 
The micro-organisms identified in contaminated nebulisers are similar to the micro-organisms 
from air samples taken around the patient’s bedside where nebulisers are kept.  
 
1.6 RESEARCH AIM 
The aim of this study is to determine the current incidence of contamination of nebulisers used 
within a ventilator circuit and surrounding air in ICUs in Pretoria and to determine the current 
practice regarding decontamination and storage of such devices. 
 
1.7 RESEARCH OBJECTIVES 
 
1.7.1 To examine which types of nebulisers and which nebulised medications are being used in 
ICUs   in Pretoria. 
 
1.7.2 To determine whether staff in ICUs are informed regarding the correct application of nebulisers 
used in MV circuits. 
 
1.7.3 To determine whether a formal nebuliser decontamination protocol exists in these ICUs and of 
the protocol is part of daily practice in these ICUs. 
 
1.7.4 To determine the incidence of contamination of jet nebulisers after use within a ventilator circuit 
in ICUs in Pretoria.  
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1.7.5 To identify which practices are associated with bacterial growth, higher concentrations of      
bacteria and multiple species within nebulisers that were used or re-used. 
 
1.7.6 To identify the micro-organisms in contaminated nebulisers used within ventilator circuits. 
 
1.7.7 To identify the micro-organisms in selected air samples where patient’s nebulisers are kept. 
 
1.7.8 To determine whether there is some correlation between micro-organisms cultured from 
contaminated nebulisers and the surrounding air. 
 
1.8 SIGNIFICANCE OF THE STUDY 
Determining the incidence of contamination of the different types of nebulisers used within 
ventilator circuits by physiotherapists and nursing staff will highlight current practice relating to 
nebuliser care in ICUs in Pretoria, South Africa.  
 
Establishing current practice in nebuliser decontamination and storage protocols as well as 
identifying micro-organisms contaminating nebulisers and surrounding air, will provide a 
platform for development of evidence based protocols for in-line nebuliser usage, 
decontamination and storage.  The implementation of evidence based decontamination and 
storage protocols may contribute significantly to the prevention of VAP in these ICUs as 
previous studies have highlighted the link between contaminated nebulisers and the incidence 
of VAP (Ball et al., 2005; Dhand, 2008). 
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CHAPTER 2  
2. LITERATURE REVIEW 
 
2.1 INTRODUCTION 
The literature reviewed in this chapter is organised according to the following sections: 
inhalation therapy, types of nebuliser devices, pathogens leading to VAP, role of hospital air 
and infection control protocols to provide the background for this study.  The main search 
engines used to identify the literature included:  Google scholar, Science Direct, PubMed, 
Ebsco Host.  Papers published between 2000 and 2013 were reviewed as well as references 
within these papers and cited on the basis of their relevance.   
 
In this literature review information on this study topic was identified by using the following 
search terms: “ VAP”, “aerosol devices”, “contamination of respiratory devices”, ” jet nebuliser”,  
“single-patient-use-devices”, “single-use-devices”, “aerosol therapy”, “decontamination of 
respiratory devices”, “inhalation therapy”, “aeroneb device”, “inhalation drugs”, “position of 
nebuliser in ventilator circuit”, “aerosol particle size of aerosol devices”, “prevention of VAP”, 
“nebuliser re-use”, “microbial colonization of respiratory devices”, “airborne transmission of 
organisms”, “microbial air contamination”, “healthcare environment”, “hospital air”, “pathogens 
in hospital air”, “pathogens causing VAP”, “air-sampler”, “hospital surface environment”, 
“airborne and surface-bound contamination”, “infection control”, “management of VAP”, 
“ventilator circuit”, “aerosol therapy during mechanical ventilation”, “bronchodilator therapy in 
mechanically ventilated patients”.   
 
2.2  INHALATION THERAPY 
The inhalation of aerosolised medications, is an ancient method of drug therapy delivery, that 
was used for the treatment of respiratory tract diseases and dates back as far as 4 000 BC.  
Ayuravedic literature indicates that inhalation therapy was used for the relief of asthma 
symptoms (Rau, 2004).   
 
Since  the 20th century, inhalation therapy has become a very important method of delivering 
drugs to the respiratory system (Rau, 2004).  Extensive developments have been made 
regarding the type of devices as well as the spectrum of medications that can be aerolised, 
which includes respiratory and non-respiratory medications (Rau, 2004).  The current methods 
of delivering aerosol therapy to ventilated patients in South African ICUs are metered-dose 
inhalers (MDIs) and nebulisation (Ellis et al., 2013).   
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The delivery of aerosolised medication is probably the most important adjunctive therapy for 
patients with respiratory disease on MV.  The goal of aerosol therapy  is to reverse the 
underlying pathology and/or to stabilize gas exchange (Kallet, 2013).  A recent international 
survey indicated that 95% of intensivists in the ICU implement aerosol therapy for the 
pharmacological management of various pulmonary diseases during MV (Ehrmann et al., 
2013).   
   
The most important advantage of aerosol therapy is the delivery of low doses of aerosolised 
drugs   to the  airway surfaces for a localised effect that leads to a rapid clinical response 
(Dolovich & Dhand, 2011).  The risks however, may include local side effects such as 
bronchospasm and delayed systemic effects, such as tachycardia and tremors depending on 
the type of medication administered (Ellis et al., 2013).   
 
2.2.1 Types of Nebuliser Devices used during Mechanical Ventilation 
Nebulisation of medication in liquid form and inhalation of medication as a pressurised gas, are 
the two primary methods of delivering aerosolised drugs to patients on MV.  Three types of 
devices are used for nebulisation of liquid medication within a ventilator circuit namely jet, 
ultrasonic and vibrating-mesh nebuliser (VMN). The device adapted for inhalation of 
medication as a pressurised gas  within a ventilator circuit is the pMDI (Michalopoulos, 
Metaxas, & Falagas, 2011).  The jet nebuliser is the most frequently used device within a 
ventilator circuit in the ICU, followed by the ultrasonic and more recently the VMN (Ehrmann et 
al., 2013).  These devices produce aerosols of different particle sizes and consequently result 
in different depths of penetration within the respiratory tract (Dhand, 2008; Robinson, Athota & 
Branson, 2009; Ari, Areabi & Fink, 2010).  During the operation of a jet nebuliser, compressed 
gas (usually oxygen) is responsible for the atomisation of the liquid medication in the nebuliser 
chamber.  The nebuliser is connected to a port on the ventilator, which diverts flow through the 
nebuliser (Ellis et al., 2013).   This pressurised oxygen is delivered as a jet stream through the 
bottom of the nebuliser chamber, creating a region of negative pressure.  The drug solution is 
routed by the gas stream, in the form of a liquid film, towards the baffle at the top of the 
nebuliser chamber.  The unsteady film breaks into particles as it is projected against the baffle.  
Small particles form an aerosol which is injected into the oxygen stream and exits at the top of 
the nebuliser.  The small aerosol particles are inhaled by the patient while the larger particles 
are diverted back to the liquid in the chamber, where it can be re-nebulised into smaller 
particles (Hess, 2000; Ari et al., 2010).   
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“Picture taken from Amazon webpage [http://www.amazon.in/Omron-NE-C28-Compressor-     
Nebulizer/dp/B0074I7AYA] [accessed on - 08.02.2015]” 
Figure 2.1: Function of the Jet Nebuliser   
 
The MICRO MIST® small volume nebuliser manufactured by Hudson RCI is a jet nebuliser 
and can be used for aerosol therapy in the ambulatory patient (hand-held) and during MV.  The 
nebuliser consists of a nebuliser cap, nebuliser chamber where medication is instilled and the 
loose baffle in the basis of the chamber.  The nebuliser is connected at the nebuliser air-inlet 
connector with tubing to the ventilator port from where the compressed oxygen is transported 
to the nebuliser.  According to the Surgical Materials Testing Laboratory (SMLT), Hudson RCI 
and Henleys have performed validation studies and have demonstrated that the MICRO 
MIST® small volume nebulisers may be re-used on the same patient three times a day for 30 
days.  However, the medical and nursing staff clean the nebuliser according to instructions 
after every treatment. Hudson RCI however emphasised that the cleaning procedure does not 
sterilise the nebuliser and recommend that the nebuliser should be discarded and replaced by 
a new nebuliser with every treatment, if the patient has an infectious disease (SMLT, 2000).  
 
 
 
 
 
 
 
 
 
 
 Figure 2.2: The MICRO MIST® Small Volume Nebuliser with Tee connector 
Baffle 
Compressed 
Oxygen 
  
O 
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The nebuliser is connected to the ventilator circuit with a Tee Connector illustrated in Figure 
2.2.  The Neb-Tee is a different Tee Connector which is a spring-loaded, self-opening and 
closing adaptor which allows the nebuliser to be connected without breaking the circuit or 
interrupting ventilation.  The Neb-Tee is instilled into the ventilator circuit and left in place and 
therefore a single-patient-use device.  The valve of the Neb-Tee adaptor opens/closes 
automatically upon insertion/removal of the nebuliser and thus helps to prevent the patient’s 
aerosol from leaking into the ICU environment (Teleflex, 2014).  
 
The ultrasonic nebuliser uses a piezoelectric transducer to produce ultrasonic waves through 
the use of electric current.  This action results in the formation of standing waves.  The crests 
of these waves are transmitted to the nebuliser chamber in which the liquid medication is 
housed and breaks the liquid into gas particles which are inhaled by the patient (Dolovich & 
Dhand, 2011).  An advantage of the ultrasonic nebuliser is the higher rate of aerosol output 
and shorter duration of therapy compared to the jet nebuliser (Kallet, 2013).  
 
The vibrating-mesh nebuliser is the latest nebuliser introduced to the aerosol therapy 
generation.  The VMN uses electricity to vibrate plates with multiple micrometre-sized 
apertures through which liquid drugs are extruded to generate aerosols.  Vibrating-mesh 
nebulisers do not heat the liquid during atomisation and are classified as passively or actively 
vibrating nebulisers (Elhissi et al., 2013).  The Aeroneb Pro vibrating-mesh nebuliser is 
specifically recommended for delivery of drugs during MV (Fink, Schmidt & Power, 2001a; 
Pederson et al., 2006).  The Aeroneb Pro vibrating-mesh nebuliser is an actively vibrating 
nebuliser and operates via a micro-pump system which employs a mesh plate with up to 1000 
dome-shaped apertures. This perforated plate is surrounded by a ceramic vibrational element 
which contracts and expands upon application of electrical current.  The result is upward and 
downward movements of the perforated plate by a few micrometres, which extrudes the liquid 
through the mesh pores, generating an aerosol which is inhaled by the patient (Ghazanfari et 
al., 2007; Elhissi et al., 2013; Najlah et al., 2013). The VMN was used less than the jet 
nebuliser and ultrasonic nebuliser in an international survey.  Ehrmann et al. (2013) suggested 
that cost could be the reason why they are used less. In South Africa the cost of the Aeroneb 
nebuliser is almost ten times the price of the Micro Mist small volume nebuliser with Tee 
Connector.  The price according to a private hospital group is ±R500 for the Aeroneb®Pro 
nebulisers and ±R50 for the Micro Mist® small volume nebuliser with Tee Connector.  
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The Aeroneb® Solo System is a VMN device manufactured by Aerogen that has a 
combination of re-use and single-patient-use components.  The Aeroneb® Solo System, which 
consists of the Aeroneb® Solo nebuliser and the Aeroneb Pro-X controller, is a nebuliser 
system designed for use within mechanical ventilators.   It is used for aerolising physician-
prescribed medications for inhalation which are approved for use within general nebulisers.  
The Aeroneb® Solo nebuliser is for single-patient-use and the Aeroneb® Pro-X controller is for 
re-use.   The Aeroneb® Solo nebuliser consists of a nebuliser unit (aerosol generator and 
plug) and the Tee Connector and should be replaced between patients (Aerogen, 2014). 
 
 
 
 
 
 
 
 
 
                   
 Figure 2.3:  Aeroneb ®Solo Nebuliser and Tee Connector 
 
 
 Figure 2.4:   Aeroneb®Pro-X controller 
 
Pressurised metered-dose inhalers are convenient, portable and multi-dose devices that 
employ a propellant under pressure to generate aerosol through an atomisation nozzle.  In a 
ventilator circuit the pMDIs are applied to the inspiratory limb of the ventilator, using a 
compatible spacer device (Dolovich & Dhand, 2011).  These devices are less expensive, 
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provide a reliable dose, require a shorter time to administer and do not pose a risk to bacterial 
infection.  Furthermore if a collapsible cylinder spacer is used within the ventilator circuit no 
disconnection is necessary which decreases the possible risk of infection and development of 
pneumonia (Dhand, 2007).  In spite of the advantages of using MDIs in mechanically ventilated 
patients, this method of drug administration has not gained universal approval among intensive 
care unit physicians.  It is believed that drug deposition in the ventilator circuit and 
endotracheal tube makes this device less effective (Georgopoulos et al., 2000).  Georgopoulos 
et al. (2000) showed that with the correct technique of administration and the use of a spacer 
when applied during MV, MDIs are as effective as nebulisers, despite a significant lower output 
dose. Ehrmann et al. (2013) reported results of an international survey on ICU physicians’ use 
of aerosol therapy during MV.  The results showed that jet nebulisers (55%) were mostly used, 
followed by ultrasonic (44%) and less frequently vibrating mesh nebulisers (14%). Results 
indicated that 55% also used pMDIs and that only 2% used MDI exclusively.   
 
2.2.2 Single-Use versus Single-Patient-Use Devices 
Single-use nebulisers are intended for one treatment only and should be discarded after use 
while single-patient-use nebulisers are devices that can be safely re-used by the same patient 
(Therapeutic Goods Administration, 2006). Single-patient-use devices must never be 
reprocessed or be used on another patient (NHS, 2012).  When using a single-patient-use 
nebuliser the manufacturer’s guidelines regarding the method of cleaning and the extent by 
which the device can be used should be followed. 
 
Reusable nebulisers can be used on different patients following the appropriate reprocessing 
between patients as indicated by the manufacturer (Kendrick, Johns & Leeming, 2003).   
 
 Reprocessing is the process by which a device is made available for safe re-use and includes 
any or a combination of the following methods; cleaning, disinfection, decontamination, 
sterilisation, refurbishment and repackaging (MHRA, 2013).  
 
The Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom 
has published a document on single-use medical devices, which states that a device 
designated as “single-use” must not be re-used.  The device should only be used on an 
individual patient during a single procedure and then discarded.  The re-use of single-use 
devices can affect their safety, performance and effectiveness, exposing patients and staff to 
avoidable risks (MHRA, 2013).   
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NON-STERILE 
The re-use of single-use devices has legal implications and medical staff will bear the full 
responsibility for the safety and effectiveness when re-using single-use devices.  In the case 
where the re-use or altered use of these devices results in an adverse reaction, the healthcare 
provider will be liable (Allen et al., 2005).  Therefore, the packaging of the device must be 
checked for the symbol which means do not re-use/use only once/single use (MHRA, 2013).  
  
 
         
 
“Do not re-use”, “single use”, or “use only once” 
 
Single-use devices can also be marked as non-sterile which needs processing before use 
following the appropriate manufacturer’s instructions (MHRA, 2013).  
 
 
  
“Symbol indicating that the device has not been sterilized” 
 
The “single-use only” label to nebulisers has caused a negative reaction from medical and 
nursing staff in hospitals and has resulted in manufacturers of disposable nebulisers changing 
their labelling from single-use only to single-patient-use only. The hospital staff’s current 
practice of re-using single-use nebulisers were found to be unacceptable according to 
manufacturers. With the change in labelling to single-patient-use, the nursing staff can 
continue following the same application procedures of the nebulisers but with additional 
cleaning instructions (SMTL, 2000). 
 
According to the SMLT, nebulisers that are reusable are labelled as such, and come with 
reprocessing instructions according to the reprocessing validation done by the manufacturer. 
These devices can also be used for extended periods according to the instructions, making 
costs lower.  However, there is a cost associated with the reprocessing and that reprocessing 
instructions might not be followed, which can lead to the users being liable for any adverse 
consequences. Therefore hospital staff must be aware of the manufacturer’s cleaning 
instructions for a single-patient-use nebuliser to ensure safe re-use on the same patient 
(SMLT, 2000).  
2
2
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The Infection Control Team (ICT) of the Wirral Hospital National Health System (NHS) Trust in 
the United Kingdom identified an increase in the number of methicillin-resistant 
Staphylococcus aureus (MRSA) isolates in the sputum of patients in the respiratory ward in 
February 2002.  With investigation, it was found that a number of single-patient-use nebulisers 
were contaminated with MRSA.  These nebulisers were used for as long as aerosol therapy 
was prescribed even up to four times a day and for several days to weeks.  There was no 
storage protocol in place and these nebulisers were left hanging open to the environment at 
the patients’ bedsides.  The ICT suggested that the wet nebulisers could have become 
contaminated by MRSA from patients in the same room.  The different types of nebulisers 
under investigation were marked as single-use devices but were used as single-patient-use 
devices.  Staff was also unaware that labelling of some nebulisers from the same manufacturer 
changed as older packaging were labelled differently.  It has been noted that manufacturers 
are not required to inform their users of any changes made to the labelling of devices (Allen et 
al., 2005).  The manufacturer’s recommendations of these various nebulisers included washing 
and drying after each aerosolisation and usage for up to 30 days.  However nebulisers used on 
patients with respiratory infection as well as single-use nebulisers, should be discarded after 
each use.  Following this investigation protocols for cleaning were developed at the Wirral 
Hospital NHS Trust and single-patient-use nebulisers were bought from one manufacturer and 
replaced after every 24h. The re-use of single-use nebulisers was also not permitted.   
Replacing the nebulisers every 24h were reported to be less expensive than the cost of 
cleaning them as well as assuming less than the cost implications from possible outbreaks of 
infection in the future (Allen et al., 2005).   
 
It is important to educate healthcare workers in the appropriate usage and decontamination of 
nebulisers  (Parker, 2004).  It is also suggested by Lester et al. (2004) that nebuliser cleaning/ 
disinfection/replacement education should be included in the curriculum of physiotherapy 
institutions or persons who dispense medication for nebulisations. 
 
2.2.3 Medication Used for Nebuliser Therapy during Mechanical Ventilation 
Delivering drugs through aerosol therapy during MV is being complicated by the presence of 
the endotracheal tube.  The endotracheal tube causes a decrease in the efficiency of drug 
delivery and drug losses also occur within the ventilator circuit.  Nevertheless, optimal methods 
used during the implementation of nebulisers or MDIs during MV, will ensure that drug delivery 
is as efficient as that of the ambulant, non-intubated device, its configuration with the ventilator, 
the patient’s position, synchronisation with the ventilator, ventilator circuit conditions and 
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ventilator settings (Dolovich & Dhand, 2011).  Ehrmann et al. (2013) reported that evidence 
from various studies have provided data for developing practices that are associated with an 
increase in efficacy and/or safety of aerosol therapy during MV (Dhand, 2004; Dhand, 2008; 
Dolovich & Dhand, 2011). 
 
A long list of drugs are administered as aerosols to patients receiving MV that includes 
bronchodilators,  prostaglandins,  corticosteroids,  mucolytics,  proteins,  surfactant,  
antibiotics, antibacterials, antifungals and a number of diverse agents  for e.g. aerosolised 
insulin (Dhand, 2007; Khilnani & Banga, 2008).  
 
Bronchodilators are the most frequently used drugs in patients with asthma or chronic 
obstructive pulmonary disease (COPD) receiving MV (Dhand, 2007).  The administration of 
bronchodilator therapy to patients with COPD during MV with either a nebuliser or pMDI has 
shown to improve respiratory mechanics (Dhand, 2007). Indications for the use of 
bronchodilator administration in MV include the following conditions; acute bronchospasm or 
wheezing, increased airway resistance, dynamic hyperinflation, weaning difficulties or 
ventilator dependence. The aims of bronchodilator therapy are to decrease the work of 
breathing, alleviate bronchoconstriction and dyspnoea.  
 
An international survey representing 611 departments in 70 countries, which included South 
Africa, showed that bronchodilators were the most common delivered drugs followed by 
steroid therapy in MV (Ehrmann et al., 2013).  Aerolised bronchodilators and steroids are 
recommended as supportive treatment for patients suffering from COPD.  Aerolised antibiotics 
were used by 30% of respondents in more than five patients a year and in some departments 
this was a general practice specifically for colistin (Ehrmann et al., 2013).  Ellis et al. (2013) 
found that bronchodilators (76%) followed by mucolytics (21%) were mostly administered to 
ventilated patients in ICUs in Johannesburg, South Africa. Combivent (bronchodilator) was the 
medication mostly used and Bisolvon (mucolytic) was the only drug that contained 
preservatives.  It was reported in this study that a nebuliser that was stored wet due to 
residual Bisolvon did not present with bacterial growth (Ellis et al., 2013).  These findings 
support the hypothesis put forward by Oie et al. (2006) that preservatives may assist in the 
inhibition of bacterial growth within a nebuliser if no decontamination has been done prior to 
nebulisation.  However, Oie et al. (2006) noted that some aerosol drugs with preservatives 
may have less antibacterial activity if diluted and that microbial contamination of the nebuliser 
is still a possibility.  
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The use of aerosolised antimicrobial agents for the treatment of VAP has gained much 
attention.  This is mainly due to nosocomial micro-organisms developing quick resistance to 
various systemic antimicrobials in ICUs.  Aerosolised antimicrobials in MV can result in a 
direct deposit at the point of infection (Safdar, Crnich & Maki, 2005).  Aerosolised antibiotics 
are increasingly prescribed for the treatment of VAP caused by multi-drug resistant (MDR) 
Gram-negative bacteria (Abu-Salah & Dhand, 2011). 
 
Infections caused by a range of multi-resistant Gram-negative bacteria, such as Acinetobacter 
spp. or Pseudomonas aeruginosa spp. have been successfully treated with aerosolised 
colistin and polymyxin B.  The addition of aerosolised tobramycin to systemic therapy in the 
treatment of respiratory-tract infections caused by Gram-negative bacilli has also shown more 
rapid results (Safdar, Crnich & Maki, 2005). 
 
Several evidence-based consensus groups have, however, recommended against routine use 
of aerosolised antimicrobials for prevention of VAP due to the possible promotion of 
antimicrobial resistance (Joseph et al., 2010).  Authors have also raised their concern 
regarding prophylactic aerosolised antimicrobials as early as 30 years ago (Safdar, Crnich & 
Maki, 2005).  The regular implementation of prophylactic aerosolised colistin to patients in a 
centre for cystic fibrosis (CF) has led to an unusual resistance of a strain of Pseudomonas 
aeruginosa to colistin and subsequently was transmitted to other patients in the unit. The route 
of transmission was inconclusive and it was suggested that patient to patient transfer was a 
possibility (Safdar, Crnich & Maki, 2005).   
 
Aerosolized antibiotics can successfully kill bacteria in the initial stages of an infection limited 
to the airway epithelium but evidence is lacking to indicate if this would be the same for VAP 
(Joseph et al., 2010).  Aerosolised antibiotics used in addition to intravenous antimicrobials 
have shown positive results in the treatment of VAP as well as VAP caused by MDR 
pathogens whereby intravenous antibiotics alone were not effective (Abu-Salah & Dhand, 
2011).  The routine use of aerosolised antibiotics can only be recommended when 
intravenous antibiotics alone are unsuccessful (Abu-Salah & Dhand, 2011).  
 
Disadvantages of aerosolised antibiotics include acute bronchoconstriction due to 
preservatives and antioxidants when intravenous preparation is used instead of antibiotics 
specially formulated for aerosol therapy (Michalopoulos, Metaxis & Falagas, 2011).  Aerosol 
antibiotics are often more expensive than systemic antibiotics (Rubin, 2008). The 
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disadvantage of using a nebuliser is the quantity of antibiotic solution that gets wasted.  
During nebulisation a proportion is delivered to the lungs and the rest remains deposited in the 
nebuliser and tubing or escapes into the environment (Michalopoulus, Metaxis & Falagas, 
2011).  Antibiotic resistance can develop due to insufficient antibiotic concentration with the 
treatment of bacterial infections.  The low concentration of antibiotics cannot successfully kill 
bacteria and can lead to the development of resistant pathogens (MacIntyre & Rubin, 2007). 
Bacteria are very capable of obtaining genetic information through various mechanisms to 
survive in an environment where antimicrobials are being used.  These mechanisms provide a 
passage by which mobile deoxyribonucleic acid (DNA) elements can be transmitted to distant 
related bacterial species which results in the rapid development and spread of MDR bacterial 
pathogens (Mcdermott & Robert, White, 2003).  
 
Nebulisers can become colonised with more than one species of bacteria or a strain of the 
same species when exposed to the environment (Ellis et al., 2013).  Nebulisers stored wet 
and exposed to a warm environment can promote the transferral of plasmids between species 
in the chamber of the nebuliser and can promote the development and transmission of 
antibiotic resistance (Ellis et al., 2013).   Additionally if the wet nebuliser was stored and 
contained an antibiotic with multiple bacterial species, antibacterial resistance can develop in 
a shorter period (Ellis et al., 2013).  Contaminated nebulisers that were used to nebulise 
antibiotics can result in micro-organisms and antibiotics nebulised back to the patient (Prober 
et al., 2000).  
 
Antibiotic aerosols can contaminate the ICU environment with prolonged administration of 
aerosolised antibiotics in non-intubated patients and potentially lead to a selection of MDR 
micro-organisms (Prober et al., 2000; Michalopoulos et al., 2011; Kallet, 2013).  Antibiotic 
contamination of the environment through aerosolisation is a simple process and occurs 
frequently.  The concentration of antimicrobials can also accumulate in the local environment 
if doses are increased, which explains the presence of tobramycin that has been observed on 
patients’ skin (Prober et al., 2000).  Antibiotics that escape to the environment through the use 
of nebulisers are, however, unable to eradicate bacteria due to low concentration, but can 
promote resistance to environmental strains which can be transferred to other patients (Rubin, 
2008).  The contamination of the environment with aminoglycosides in the presence of 
multiple resistant Gram-negative organisms can result in a significant increase in resistance to 
tobramycin.  It has been suggested therefore, that nebulisers exhaust circuit filters and vent-
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free nebulisers should be implemented to minimise environmental contamination (Prober et 
al., 2000).   
 
2.2.4 Storage Methods of Nebulisers Used within a Ventilator Circuit 
Ellis et al. (2013) found that most nebulisers in ICUs in Johannesburg, South Africa were 
stored either in a sterile drape or covered by a latex glove.  The nebulisers stored in a sterile 
drape presented with higher concentrations of bacterial growth than nebulisers stored in a 
glove, paper bag or opened to the environment.  Although storage of nebulisers under sterile 
drapes is common practice, no evidence could be found to support this storage method.  Ellis 
et al. (2013) suggested that the increase in bacterial growth could be contributed to the dark 
environment under the drape and not the drape itself, as light inhibits the growth of some 
bacteria such as MRSA (Sheldon, Kokjohn & Martin, 2006).  
 
Storage of nebulisers in latex gloves allows for more light penetration but prevents the 
nebuliser from drying and can potentially contribute to the growth of bacteria.  This is important 
as most of the nebulisers in Ellis’ study were stored wet in the ICUs.  Only one nebuliser was 
stored with visible secretions and as expected presented with bacterial growth (Ellis et al., 
2013).   
 
Nebulisers that were stored still connected to running oxygen (1L/ml), presented with no 
bacterial growth.  Ellis et al. (2013) suggested that the reason for this finding could be either 
that the oxygen assisted in drying the chamber of the nebuliser or that the running oxygen 
inhibited bacterial growth.  The role of paper bags (obtained after a sterile pack had been 
opened) used to cover nebulisers in prevention of contamination could not be determined as 
those nebulisers were also connected to oxygen.  It has been reported elsewhere that paper 
bags has a greater absorbency than latex gloves (Fisher et al., 1999).  Ellis et al. (2013) 
suggested that paper bags could be more beneficial than gloves and sterile drapes due to their 
absorbency and increased exposure to light.  Additionally, recordings can be made on the bag 
regarding the patient’s name, date and time of aerosolisation sessions (Ellis et al., 2013).   
 
As previously mentioned, nebulisers left open to the environment can become contaminated by 
pathogens in the surrounding air (Allen et al., 2005).  Nebulisers stored wet and open can 
become contaminated with antibiotic aerosols which can result in the development of MDR 
pathogens.  Additionally, contaminated nebulisers stored wet with antibiotics solution still left in 
the chambers after aerosolisation can have the same outcome (Ellis et al., 2013). 
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2.3 VENTILATOR-ASSOCIATED PNEUMONIA  
Approximately one in seven patients admitted to hospitals in South Africa are at high risk of 
acquiring a healthcare-associated infection (HAI) (Brink et al., 2006).  Nosocomial pneumonia 
is the most common infection in ICUs and the second most common nosocomial infection in 
the world (Jadhav, Sahasrabudhe, Kalley, & Gandham, 2013).  This type of pneumonia, also 
referred to as hospital-acquired pneumonia (HAP), is defined as pneumonia that occurs ≥ 48 
hours after admission to a hospital and that was neither present nor incubating at the time of 
admission (Brink et al., 2006).  Ventilator-associated pneumonia (VAP) is the secondary result 
of intubation and MV and is preventable (Fields, 2008).  Ventilator associated pneumonia is 
further defined as early-onset (occurring in less than five days after intubation) and late-onset 
(occurring five days or longer after intubation) (Gillepsie, 2009).  The incidence of VAP differs 
between units, hospitals and countries. The incidence of VAP also varies in different units 
within the same hospital and is more prevalent in high density units (Klompas, 2007; Pieracci & 
Barie, 2007; Rea-Neto et al., 2008).  Mortality rates due to VAP vary from 20% to 50% and 
may be as high as 70% in patients with multi-resistant invasive pathogens (Gillespie, 2009).  
 
Endotracheal intubation inhibits the cough reflex, compromises mucociliary clearance, disturbs 
the tracheal epithelial surface and provides direct access for bacteria into the lower respiratory 
tract (Efrati et al., 2010).  Micro-organisms gain access to the lower respiratory tracts in 
patients receiving MV  through four mechanisms:  a) most frequently by aspiration of micro-
laden oropharyngeal, gastric or tracheal secretions around the cuffed endotracheal tube 
(Crnich, Safdar & Maki, 2005); b) adjacent contribution such as a pleural space infection (Efrati 
et al., 2010); c) inhalation of contaminated air or medication aerosols (Efrati et al., 2010); or d) 
by hematogenous transport of micro-organisms to the lung (Safdar, Crnich & Maki, 2005).  
 
 Other mechanisms that can potentially contribute to the high prevalence of VAP are unclean 
hands, apparel of healthcare workers, contaminated hospital surfaces and environment and 
respiratory equipment (e.g. nebulisers, resuscitation bags, ventilator circuits, tracheal tube), 
hospital water (Legionella spp. mostly implicated) and hospital air (e.g., Aspergillus spp. or the 
severe acute respiratory syndrome (SARS) virus.  
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 The endotracheal-tube acts as a reservoir for micro-organisms which adheres to the tube to 
produce a biofilm.  Biofilms are highly resistant to the effects of antibiotic therapy and play an 
important role in the late-onset of VAP due to the persistent colonisation of resistant organisms 
(Safdar, Crnich & Maki, 2005).  
  The architectural design of an ICU must ensure adequate space, easy to clean furniture and 
convenient locations for sinks to promote compliance with hand hygiene.  Evidence that the 
current recommendation regarding ICU design can assist in decreasing of nosocomial infection 
is greatly needed (Crnich, Safdar & Maki, 2005). 
 
Finally, studies have shown that ICUs that are inadequately staffed or staffed by temporary 
staff had increased rates of nosocomial pneumonia (NP).  The increased rates are likely due to 
increased patient-to-staff ratios with noncompliance to hand hygiene and temporary staff being 
unfamiliar with the ICU’s policies and procedures (Crnich, Safdar & Maki, 2005).  According to 
the International Nosocomial Infection Control Consortium (INICC), (2010) report, a higher 
number of days spent on ventilator in the medical-surgical ICU were associated with the high 
percentage of VAP (Rosenthal et al., 2010).  Ventilator-associated pneumonia is associated 
with increased mortality and morbidity, increased ventilator days, prolonged length of stay in 
ICUs and hospitals.  Consequently this leads to high hospitalisation costs.  In the public sector 
a stay per day in an ICU costs a minimum of R5000 in South Africa (Gillepsie, 2009). 
 
 2.3.1 Pathogens that Lead to the Development of VAP  
The early-onset of bacterial NP develops within the first four days in patients with no risk 
factors for multidrug-resistant bacteria, and are usually caused by Streptococcus pneumoniae, 
Haemophilus influenzae, methicillin-sensitive Staphylococcus aureus and Moraxella catarrhalis 
(Brink et al., 2006).  Antibiotic-sensitive enteric Gram-negative bacilli such as Enterobacter 
spp., Escherichia coli, Klebsiella spp., Proteus spp. and Serratia marcescens are also 
responsible for early-onset of bacterial NP.  These pathogens can also occur in the late-onset 
of bacterial NP, but are usually due to methicillin-resistant Staphylococcus aureus (MRSA) and 
other multi-drug-resistant pathogens which include Pseudomonas, Acinetobacter and 
Klebsiella spp. (including isolates producing extended-spectrum beta-lactamase) (Brink et al., 
2006).  Pseudomonas aeruginosa and Acinetobacter anitratus occur slightly later in the 
patient’s stay in ICU and are a serious cause of VAP.  Specific risk factors are associated with 
these pathogens such as prolonged hospital stay, prior antibiotic therapy and severe 
underlying diseases. (Feldman, 2005).  The frequency of MDR Gram-negative bacteria and 
MRSA in VAP are increasing in the ICUs (Abu-Salah & Dhand, 2011).  Other common causes 
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of VAP include infection by Enterococci and Coagulase-negative Staphylococci (CoNS) 
(Joseph et al., 2010).  Enterococcus spp. are generally seen as part of the normal flora of the 
gastrointestinal and genitourinary tract of the body, however, they have emerged as one of the 
leading causes of nosocomial infections and shows an increase in multi-drug resistance 
(Prakash, Rao & Parija, 2005).  Other pathogens that may also cause VAP, even though to a 
lesser extent, include fungi e.g. Candida and Aspergillus spp. and pathogens such as 
Legionella spp. (Feldman, 2005).  Uncommon pathogens causing VAP includes the Herpes 
simplex virus, Mycoplasma pneumonia, Neisseria spp., Pneumocystis jiroveci etc. (Joseph et 
al., 2010).  The approximate frequency with which these micro-organisms cause NP is; Gram-
negative bacilli (40-75%), Gram-positive cocci (5-30%) anaerobes (1-5%), fungi (1-5%) and 
other pathogens which include Legionella spp. and Moraxella catarrhalis (0-5%) (Feldman, 
2005).  Other factors contributing to the development of nosocomial infections are patient 
susceptibility and bacterial resistance (WHO, 2002).  
 
2.3.2  The Role of Contaminated Nebulisers in the Development of Ventilator-Associated                       
Pneumonia 
Various studies, as early as the 1960s, have identified aerosols produced by nebulisers as a 
possible source of VAP (Reinarz et al, 1965; Edmondson, Reinarz & Pierce, 1966; Craven et 
al., 1984).  In addition, early systematic reviews and other reports indicated the relationship 
between nosocomial infection and bacterial contamination of nebulisers and other apparatus 
used for the treatment of respiratory infections in hospitals (Mertz, Scharer, & McClement, 
1967; Phillips & Spencer, 1965; Ringrose et al., 1968).   
 
Ellis et al. (2013) reported that 52% of nebulisers that were used within ventilator circuits in 
ICUs in Johannesburg presented with bacterial growth.  Single-use jet nebulisers were mostly 
used and all were being re-used although they were marked as single-use devices.   
 
Jadhav et al., (2013) studied the microbial contamination of respiratory equipment including 
nebulisers used in the ICUs, wards, casualty, and outpatient departments.  Bacteria were 
isolated in 47.5% of the nebuliser swabs taken from their chambers.  The total number of 
bacterial isolates collected from the various respiratory equipment indicated that 87.14% were 
Gram-negative and 31.14% were Gram-positive cocci.  The micro-organisms identified in the 
chambers of nebulisers included: Pseudomonas spp., Acinetobacter spp., Klebsiella 
pneumoniae, Escherichia coli and Stenotrophomonas maltophila, MRSA, Methicillin sensitive 
Staphylococcus aureus (MSSA), CoNS (Jadhav et al., 2013).  
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Oie et al. (2006) found that 26.3% of nebuliser solutions showed microbial contamination due 
to the use of contaminated ultrasonic nebulisers.  Microbial contamination was significantly 
lower when disinfection of the ultrasonic nebulisers was performed at 24-h intervals.  
Additionally the use of multi-dose medication vials and the rinsing of nebuliser chambers with 
tap water may contribute to contamination of nebulisers and result in the development of VAP 
(Tablan, 2003). 
 
No research could be found regarding contamination rates of VMNs when used in ventilator 
circuits. These nebulisers have only recently been introduced to ICUs in South Africa and 
specifically to ventilator circuits.  There also seems to be a lack of knowledge regarding the 
role that physiotherapists should play in the decontamination of jet nebulisers, the protocols 
they should use and their adherence to these protocols. This is of great importance as 
physiotherapists use nebulisation as a source of medication on a regular basis as a technique 
in patients receiving MV in ICUs in South Africa (Ellis et al., 2013). 
 
2.4 HOSPITAL AIR 
The indoor quality of air in hospitals has become an important part of hospital management 
protocols.  Healthcare-associated infections caused by transmission of pathogens through the 
airborne route have gained much attention in the last two decades.  Critically ill patients that 
are exposed to airborne pathogens may be more susceptible to cross-infection and this can 
result in a significant increase in morbidity and mortality (Huang et al., 2013).  This is of great 
concern especially in the hospitals in South Africa where human immunodeficiency virus (HIV) 
and tuberculosis (TB) occurs in high numbers (Setlhare et al., 2014). 
 
The main pathogenic micro-organisms resulting in healthcare-associated infections by airborne 
transmission includes fungi such as Aspergillus flavus, Gram-negative bacilli such as Neisseria 
meningitidis, Serratia mascescens, Staphylococcus aureus, Streptococcus pyogenes, 
Streptococcus pneumoniae and Tuberculosis bacilli (Kim, Kim & Kim, 2010).  
 
Pathogens in the air can be transported on particles derived from skin or droplets  generated 
from the upper or lower respiratory tract, mouth, nose or droplets generated through vomiting, 
and diarrhoea (Eames, Tang, Li, & Wilson, 2009).  Creamer et al. (2014) identified MRSA from 
air samples mainly in ward bays where MRSA-positive patients were hospitalised.  Samples 
taken from patients or environment which included mattresses, bedrails and locker detected 
MRSA in 50% cases which suggest dispersal from patient to the surrounding air.  Mattresses 
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were the item from which MRSA was mostly isolated.  Methicillin-resistant Staphylococcus 
aureus are also able to survive on hospital surfaces for long periods and may be transmitted to 
patients and/or environment. Patients appear to shed skin scales more during the night and 
early mornings and can be dispersed over great distances with lengthy activities such as bed 
making.  Higher rates of MRSA were detected in both air and surface samples early in the 
morning (Creamer et al., 2014.).  Huang et al. (2013) studied airborne and surface-bound 
microbial contamination in two ICUs.  Pseudomonas aeruginosa was identified as the most 
frequently isolated bacterium on surface and in air samples and was the only pathogen 
indicating a positive correlation of mean counts between both samples.  The ventilator 
presented with the most contamination in both total pathogenic bacteria colony counts and 
frequency of positive detection.  The order of positive detection frequency for the four bacteria 
identified in the air samples corresponded with both bacteria isolated from surface samples 
and the percentage of patients infected by the same bacteria (42% for Pseudomonas 
aeruginosa and Escherichia coli, 35% for Staphylococcus aureus, and 33% for Acinobacter 
baumannii).  Furthermore, mean airborne counts and detection frequencies of these bacteria 
were higher after patient visitation periods (Huang et al., 2013).  
  
Gaudart et al. (2013) studied the environmental variability of micro-organisms in a medical ICU 
and surgical ICU by measuring the total viable count on surfaces and in the air.  The total 
viable counts of air and surface samples were generally higher in the medical ICU.  Colony 
counts in the air and surface samples varied between height, locations, bedside area and bed 
occupancy. Severity of illness was a constant predictor of contamination. Surface 
contamination is affected by aero-contamination as some pathogens will eventually settle on 
surfaces.  Pathogens in the air can be distributed across a room at different distances due to 
air movement (Gaudart et al., 2013).  Organisms that have settled on surfaces may be 
transferred to other surfaces by touch or air currents generated by human movement in the 
unit.  The air and surfaces within bed spaces were found to be consistently highly 
contaminated (Gaudart el al., 2013).  Larger respiratory droplets can fall on the ground and 
contribute towards dust particles which can be suspended and re-suspended by activities such 
as dressing, sweeping or bed-making (Hobday & Dancer, 2013).  
 
Filamentous fungi and moulds are the main pathogens commonly found in ambient air, 
including hospital air (Safdar, Crnich & Maki, 2005).  Aspergillus fumigatus, Aspergillus flavus, 
Aspergillus terreus are being recognized as common causes of nosocomial infections (Jadhav 
et al., 2013).  
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Nosocomial infections caused by filamentous fungi are mostly acquired through air 
transmission (Crnich, Safdar & Maki, 2005).  Outbreaks through this route have been related to 
breakdowns in hospital air-handling systems (Lutz et al., 2003) and during periods of hospital 
construction (Panackal et al., 2003). 
The survival of pathogens in the air depends on multiple factors such as residence time in the 
air, humidity, temperature, UV light and other atmospheric pollutants (Eames et al., 2009).  
Furthermore, airborne droplets can be distributed by the movement of people and their clothes, 
opening of doors, ventilation systems and electrical equipment producing thermal gradients 
(Eames et al., 2009).  Most of the pathogens that cause airborne infection cannot tolerate 
sunlight. Streptococci can survive for only five minutes in direct sunlight and over an hour in 
diluted daylight whereas sunlight kill Staphylococci within 70 minutes of direct exposure 
(Hobday & Dancet, 2013).  Streptococci and Staphylococci are both Gram-positive cocci and 
are causes of early onset of VAP (Feldman, 2005).   
 
In the pre-antibiotic era the hospitals were designed to allow fresh air and sunlight to reduce 
the possible risk of infection.  Today modern healthcare settings are sealed insulated 
structures with forced ventilation that may favour the persistence and transmission of 
pathogens (Eames, 2009; Hobday & Dancer, 2013).  Further research is needed to evaluate 
the risks associated with airborne pathogens in the healthcare setting and the potential 
benefits of fresh air and sunlight on surface decontamination (Hobday & Dancer, 2013).  The 
lack of reports regarding  the distribution and extent of microbial contamination of hospital air in 
South Africa is a concern  especially with the increase risk of acquiring hospital-acquired 
infection (HAI) through airborne route and the emergence of drug resistance to infectious 
diseases (Setlhare et., 2014). 
 
Providing ventilation to buildings is the process whereby outdoor air are supplied and 
distributed through the building and at the same time diluting and removing pollutants 
emerging from within the building (Eames et al., 2009).  The conservation of adequate air 
exchange rates which refers to rate by which outside air replaces indoor air in a building 
together with air filtering has become  important methods used in ventilation systems to ensure 
air quality in hospitals (Huang, 2013).   Most hospitals use negative pressure isolation for areas 
highly exposed to infection such as operating theatres and ICUs.  This method of ventilation 
assists in controlling and preventing the transmission of exogenously-acquired healthcare-
associated infections (Huang, 2013). 
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Air purifiers include filtration units and chemical oxidisers (e.g., ozone and ionised air) and 
have also been used in clinical settings to control microbial contamination (Huang, 2013).  
High-efficiency particulate air (HEPA) filters have been shown to reduce the airborne 
concentration of Aspergillus spp. and fungal levels (Mahieu et al., 2000; Araujo et al., 2008).  
Recently an automated air disinfection system has shown to reduce both airborne microbial 
counts and environmental contamination in the hospital environment.  This system produces 
hydroxyl radicals which have shown disinfection characteristics.  Ventilation systems can 
become contaminated due to inadequate maintenance and poor design and have been 
associated with outbreaks of tuberculosis and MRSA (Hobday & Dancer, 2013). 
 
2.5 FUNGAL INFECTIONS IN THE HOSPITAL SETTING 
Fungal infections are increasingly becoming common in hospitals today, and more prevalent in 
ill patients especially in the ICUs.  The National Nosocomial Infections Surveillance system 
report indicated a constant increase in the rate of nosocomial infection from January 1992 to 
June 2004.  It is believed that fungi take the lead in infecting the immune-compromised patient 
who is usually well covered with antibiotics (Jadhav et al., 2013). 
 
Jadhav et al. (2013), indicated another potential risk of fungal cross-infection.  In the study, 
swabs were obtained from the inner surfaces of the oxygen humidifiers and Hudson nebuliser 
chambers in the ICUs, general wards, casualty and outpatient departments.   A total of 53/70 
(75.71%) fungal isolates were identified of which the ICUs presented with the highest growth 
23/33 (69.70%).  The ICUs included the medical ICU, surgical ICU and neonatal ICU.  
Aspergillus fumigatus (33.96%) was predominantly isolated, followed by Aspergillus niger 
(18.86%).  The following fungal isolates were identified in swabs taken from the chambers from 
nebulisers: Aspergillus fumigatus, A. niger, Fusarium spp., Chaetomium spp., Streptomyces 
spp. and Candida spp.  There are several reports on the on-going prevalence of non-albicans 
Candida among hospitalized patients (Jadhav et al., 2013). 
 
As previously mentioned certain Aspergillus spp. have become familiar causes of nosocomial 
infections.  Aspergillus species are ever-present and it can also be found in unfiltered air, 
ventilation systems, oxygen humidifiers, nebuliser tubing as well as dust from construction, 
carpeting, floor and ornamental plants.  Hyalohyphomycosis e.g. nondematiaceous moulds 
have also recently been recognised as pathogens causing nosocomial infections (Jadhav et 
al., 2013).  Nebuliser chambers colonized by fungi can result in the direct delivery of fungal 
pathogens to the patients’ airways (Jadhav et al., 2013).  
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2.6 INFECTION CONTROL AND DISINFECTION PRACTICES 
Infection control in the ICU emerged from hospital-wide infection-control programs due to the 
Staphylococcal pandemic of the late 1950s and early 1960s (Warren & Kollef, 2005).  The 
increasing rates of healthcare-related infections and antibiotic resistance today (Dettenkofer & 
Spencer, 2007) and the importance of infection control is a field of great concern for healthcare 
professionals (Ellis et al., 2013). 
 
The implementation and quality of infection control programmes varies across healthcare 
institutions in South Africa and the costs associated with HAIs drain the already limited 
financial reserves assigned to healthcare (Brink et al., 2006).  Health-care professionals in the 
ICU need an infection-control policy that is well explained, evidence-based, and eagerly 
accepted by all staff.  Leadership in the ICU and hospital is responsible to set a culture of 
cooperation (Warren & Kollef, 2005).  
 
The hands of health-care professionals are the most common vehicle for the transmission of 
healthcare-associated micro-organisms between patients and within the healthcare 
environment.  Hand hygiene is the most important measure for preventing the spread of 
antimicrobial resistant micro-organisms and for reducing healthcare-associated infections 
(Allangranzi & Pittet, 2009).  Washing hands is therefore an important infection control and 
safety measure.  Hands need to be washed as meticulously and promptly between patients 
and after contact with respiratory care equipment that are contaminated by them such as 
nebulisers, ventilators and humidifiers (Jadhav et al., 2013).  An investigation of an outbreak of 
Candida tropicalis fungaemia in a neonatal intensive care unit (NICU) was reported in 
neonates who received parenteral nutrition and antibiotic therapy.  Hand washing is an 
important infection control measure as Candida tropicalis was isolated from two NICU workers 
and not from the NICU environment (Jadhav et al., 2013).  Hand hygiene in the ICU is 
especially important when handling critically ill patients as they are vulnerable to nosocomial 
infection due to their immune-compromised state.  Qushmaq et al. (2008) indicated that only 
20% of health-care providers (clinicians, nurses, residents and physiotherapists) adhered to 
the hand hygiene recommendations.  The highest adherence to the current recommendation 
was among the physiotherapists.  
 
Studies have indicated the association between increased nursing workload and the 
development of nosocomial infections amoung ICU patients (Dang et al., 2002; Crnich, Safdar 
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& Maki, 2005; Warren & Kollef, 2005).  Therefore it is highly important for ICUs to be 
adequately staffed to ensure compliance with fundamental infection control practices and the 
performing of essential care (Crnich, Safdar & Maki, 2005).  Studies worldwide have not 
highlighted the role that the staffing levels of other healthcare-care professionals including 
physiotherapists play in the incidence of nosocomial infection (Warren & Kollef, 2005).  
Therefore, it is highly important for ICUs to be adequately staffed to ensure compliance with 
fundamental infection control practices and the performing of essential care (Crnich, Safdar & 
Maki, 2005).  
 
Ramsey et al. (2001) indicated that physiotherapists sharing multidose albuterol vials among 
several patients in a community hospital were associated with the outbreak of Burkholderia 
cepacia.  Burkholderia cepacia was grown from cultures taken from three previously opened 
multidose vials. Nebulisers were not dried between aerosolisation sessions and probably 
contributed to the outbreak.  It was suggested that physiotherapy departments in the hospital 
must emphasize the adherence to infection-control protocols, particularly among temporary 
and new physiotherapy staff (Ramsey et al., 2001).   
 
The four steps in nebuliser care according to the Cystic Fibrosis Foundation (CCF) includes; 
cleaning, disinfecting, rinsing and air drying if permitted by the manufacturer (O’Malley, 2009).  
There are several disinfection protocols, but the protocol followed must be permitted by the 
manufacturer’s guidelines.  Tap water can only be used for the cleaning process prior to 
disinfection and not be used for the final rinse.  Furthermore the final rinse must be done with 
sterile water as distilled water is only regulated to prevent coliform bacteria (e.g. Klebsiella, 
Enterobacter and E. coli) (O’Malley, 2009).  O’Malley found that the hospital nebuliser cleaning 
protocol used for patients with (CF) conflicted with the CCF recommendations.  O’Malley, 
(2009) studied the nebuliser protocol followed in the Children’s Memorial Hospital in Chicago 
and found it was safe.  There was no contamination found in nebulisers with Pseudomonas 
aeruginosa, Staphylococcus aureus, Haemophilus influenza or Burkholderia cepacia after it 
has been re-used without cleaning for 24h and then replaced. 
 
Jadhav et al. (2013) found that contamination levels dropped significantly after nebuliser 
chambers were washed with soap and distilled water prior to disinfection with 70% alcohol.  
After implementing this protocol the fungi colonisation rate dropped from 70% to 15% and the 
bacterial colonisation rate from 75% to 12%.  This protocol was done with strict compliance to 
hand hygiene (Jadhav et al., 2013). 
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Delivering care to the critically ill patient is complex, therefore policies and procedures are 
needed to assist in the organisation of any ICU.  These ICU policies should include evidence-
based infection control practices which demonstrate prevention or reduction of nosocomial 
infections.  Almost all international accreditation programs for private as well as state hospitals 
base their review of ICUs not only on policies by law, but also whether these policies are 
adhered to.  To succeed in the implementation of ICU policies, the policies should be easy to 
follow, easy to understand and realistic (Warren & Kollef, 2005).  
 
 Ellis et al. (2013) found that none of the ICUs in Johannesburg, South Africa had nebuliser 
decontamination protocols in place and that ICUs differ in their methods of storing re-used jet 
nebulisers.  Physiotherapists play a vital role in the respiratory management of patients 
receiving MV in the ICUs.  It is recommended that nursing staff and especially physiotherapists 
should be informed regarding the possible contamination of nebulisers used in ventilator 
circuits as nebulisation is used to either assist in the clearance of secretions or relieve 
bronchospasm while patients receive MV.   
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CHAPTER 3 
3. METHODOLOGY 
 
3.1 INTRODUCTION 
The methodology followed in this study was based on a previous study undertaken by Ellis et 
al, (2013) in ICUs in Johannesburg hospitals, South Africa. 
 
In the current study, additional air samples were taken at the bed sides where nebulisers were 
kept and apart from the jet nebuliser, samples were also taken from VMNs that were recently 
introduced to ICUs in Pretoria, South Africa.  This section describes the audit tools used to 
gather information regarding nebuliser decontamination protocols and storage methods of 
these nebulisers.  Details of the study design, sample selection, instruments and apparatus 
used to collect samples from nebulisers and the surrounding air to evaluate possible 
contamination have been included.  The process of identifying bacterial and fungal colonies, 
multiple species and higher concentrations of bacteria as well as the methods used for 
bacterial culture identifications have been described.  Matters related to ethical clearance for 
the study have also been included in this chapter. 
 
3.2 STUDY DESIGN                    
A cross-sectional observational analytical study design was used to study the practise 
surrounding the use of nebulisers within a ventilator circuit and contamination levels in ICUs in 
Pretoria.  
 
3.3  SAMPLE SELECTION  
3.3.1 Hospitals 
3.3.1.1 Inclusion criteria for hospitals  
The ICU’s of private as well as government hospitals identified in Pretoria, South Africa were 
approached for participation in this study.  Three main private hospital groups were 
represented in this sample selection which included, Netcare, Life Healthcare and Medi-Clinic.  
These hospitals were selected within a geographical location to obtain a representative 
sample.  All the ICUs were randomly approached for participation within the hospitals that gave 
consent to conduct this study. 
 
  
29 
 
 
 
Hospitals that were approached for participation in this study: 
Private Hospitals: 
 Unitas Hospital (Netcare) 
 Medforum Hospital (Mediclinic) 
 The Wilgers Hospital (Life Healthcare) 
 Pretoria East Hospital (Netcare) 
 Eugene Marais Hospital (Life Healthcare) 
 Kloof Hospital (Mediclinic) 
 Zuid-Afrikaans Hospital (independent) 
 Little Company of Mary Hospital (Life Healthcare) 
 Meulmed Hospital (Mediclinic) 
 Jacaranda Hospital (Netcare) 
 Astrid Hospital  
 Moot Hospital (Netcare) 
 
Government Hospitals: 
 Steve Biko Academic Hospital 
 Kalafong Hospital 
 One Military Hospital 
 Dr George Mukhari Hospital 
 
3.3.1.2 Exclusion criteria for hospitals 
Hospitals situated outside of Pretoria, South Africa were excluded. 
 
3.3.2 Nebulisers  
3.3.2.1 Inclusion criteria for nebulisers  
Nebulisers in the ICU at the time of audit were selected for assessment.   These nebulisers 
were used within a ventilator circuit either for an endotracheal or a tracheostomy tube.   
 
3.3.2.2 Exclusion criteria for nebulisers 
Nebulisers that were kept at the patient’s bedside but not used for inhalation therapy within a 
ventilator circuit. 
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3.3.3 Sample Size 
Ellis et al (2013) conducted a similar survey in Johannesburg, South Africa and screened 269 
ICU beds.  The sample size in their study was calculated according to the estimated 
prevalence of ventilated patients in ICU set at 50%. This calculation was based on the number 
of ICU beds in Gauteng as reported by Bhagwanjee and Scribante (2007).  They found that the 
average number of ventilated patients in ICUs in Johannesburg was 4.43 (SD ± 2.94) and that 
16.7% of these patients received nebuliser therapy; a total of 45 nebulisers were identified and 
assessed.  Based on these results and in concordance with a statistician the sample size for 
the current study was set a minimum of 270 ICU beds to be screened to identify nebulisers 
used within a ventilator circuit in Pretoria.   
 
3.4 PROCESS OF OBTAINING INFORMED CONSENT  
3.4.1 Ethical Clearance 
Ethical clearance to perform this study was sought and obtained from the University of the    
Witwatersrand, Human Research Ethics Committee (HREC) prior to the study. Ethics 
clearance certificate number M120514 (Appendix 1).  The names of the participating hospitals 
were coded and kept confidential.  The data collected was only accessible by the researcher.   
Each hospital has been given the opportunity to access their results.   
 
3.4.2 Hospital Manager/Chief Executive Manager/Infection Control Manager     
The hospitals were approached and communication done via a letter addressed to the hospital 
manager/chief executive officer (CEO) and the infection control manager.  This letter included 
an information sheet to explain the nature of the study as well as a consent form (Appendix 2, 
3).  Possible participation of the hospitals was established through phone calls and meetings 
with the hospital manager/CEO/infection control manager of each hospital and confirmed by 
them signing the consent form.  The manager/CEO/infection control manager was allowed to 
decline participation of their hospital in this study. 
 
3.4.3  Intensive Care Unit Manager 
The unit manager of the selected ICUs was approached after consent was obtained from the 
hospital manager/CEO/infection control manager of that hospital.   
 
The unit managers of each ICU were identified and approached regarding the study via letter 
(Appendix 4, 5).  This letter included an information sheet to explain the nature of the study as 
well as a consent form.  After consent was obtained from the unit manager an interview was 
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set up to discuss an appropriate time and date for audit.  The unit manager was also given the 
opportunity to ask questions and to highlight any concerns regarding the procedures that were 
to be followed.   
 
3.4.4 Patients 
There was no direct contact with patients during this study and therefore no consent from the 
patient was needed. The patient’s treatments and nebulisation schedules were not altered or 
affected.  Nebulisers were returned to the patient’s bedside, in its original position and 
condition to reduce the impact on the patient’s treatment.  The use of sterile swabs and sterile 
procedures ensured minimal risk of possible contamination.  
 
3.5 PILOT STUDY 
Nebuliser and air swabbing protocols were established through a pilot study done at one of the 
participating hospitals.  Prior to the pilot study the researcher practiced methods for swabbing 
and air sampling under supervision at the University of the Witwatersrand PML laboratory to 
ensure consistency. The methods followed during the pilot study included the following: 
 
3.5.1 Swabbing and Streaking Method 
Swabbing of the blood agar plates (BAP) (Figure 3.1) with regards to the nebuliser was 
undertaken with a sterile swab by streaking on the surface from side to side in parallel lines 
across the plate without digging into the agar.  The BAPs were pre-prepared at the University 
of the Witwatersrand Pharmaceutical Microbiological Laboratory (PML).  Mueller Hinton 
powder (19g) was mixed with 500ml of distilled water and autoclaved.  The solution was mixed 
with 22.5ml (5%) sheep blood after it cooled down.  An automatic pipette was used to pour the 
blood mixture into the plates to set.  Before storing the plates in the fridge each plate was 
checked for purity, covered and stored upside down in steel baskets. 
 
Figure 3.1:  Blood Agar Plate 
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A culture medium, such as blood agar, supports the growth and development of various micro-
organisms.  Sterile sheep blood is used to enrich microbiological culture media to demonstrate 
the typical growth features of these micro-organisms such as haemolysis.  Most clinical 
microbiology laboratories use blood agar to identify the haemolytic reaction as well as colonial 
morphology of primary cultures.  This establishes a platform whereby the selection of colonies 
from primary culture for further growth, can be made.  Sheep blood is the most ideal used for 
blood enriched agar (Magbojos et al., 2011).  The following procedures and protocols to collect 
nebuliser samples were established and followed during the pilot study: 
 
The researcher followed a sterile procedure within the cubicle of the patient.  A trolley was 
used as a working station.  The trolley was wiped with 70% alcohol.  Hands were washed 
using the appropriate technique and nitrile powder free latex gloves and plastic apron were 
applied before each procedure.  Procedures were specifically followed according to the type of 
nebuliser sampled. 
 
 3.5.1.1Micro Mist small volume nebuliser 
 The Micro Mist small volume nebuliser was removed from the oxygen tubing and/or covering 
and placed on sterile gauze on the trolley.  The easy-seal threaded cap was removed and 
placed on sterile gauze.  The base plate was then removed without touching the sides of the 
chamber and also placed on the sterile gauze.  A sterile swab was dipped into the residual 
solute within the reservoir of the nebuliser without touching the sides of the chamber. The swab 
was immediately streaked across a BAP and covered.  This procedure was repeated to collect 
two sets of BAPs.   If the reservoir was dry or there was less than 2ml of liquid in the reservoir, 
2ml of 9% sodium chloride was added to the reservoir.  The BAP was marked according to 
date, time and hospital as well as type of organism to be cultured.  Each nebuliser was 
reassembled and returned to the patient’s bedside in its original position and condition.  
 
3.5.1.2 Aeroneb solo® nebuliser 
The same procedure was followed with the Aeroneb system.  The Aeroneb system is 
manufactured to stay attached within the ventilator circuit and only its plug needed to be 
opened to do swabbing of the liquid within the reservoir.  The sides of the chamber were not 
touched during the swabbing procedure.  After two sets of streaked BAPs were collected the 
plug was closed.  
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3.5.2 Method of Collecting Air Samples 
The air samples were collected with the use of an air sampler.  The Surface Air System (SAS) 
sampler (SAS International PBI, Milan, Italy) was used to collect the air samples.  The SAS 
(Figure 3.2) is considered the international standard for portable air microbiology samplers. 
The SAS sampler makes use of several models which use the same principle.  Air is aspirated 
at a fixed speed for variable time through the aspirated head which consists of small holes of a 
special design.  The laminar air flow is directed onto a contact plate.  The plate is removed, 
covered and incubated after the chosen cycle has been completed.  The organisms cultured 
after incubation are then visible to the naked eye and can be counted and assessed (SAS, 
2014). 
 
 Figure 3.2:  Air Sampler 
 
For this study the SAS sampler has been programmed to sample a constant 200 L of air for 
each air sample taken which is in line with the procedures outlined by Perdelli et al. (2008).  
The objective for collecting air samples at the bed sides of patients where nebulisers were kept 
was to determine if colony counts were similar to that found in the nebulisers and to identifying 
similar micro-organisms cultured from contaminated nebulisers and air samples. 
 
The handling and use of the air sampler were practiced at the PML to ensure the correct 
application.   This included the cleaning of the body and the chamber of the air sampler.  The 
cleaning was done by disinfecting the aspirating metal head and chamber with 70% alcohol. 
After allowing the air the SAS sampler to dry completely it was positioned upright on a stable 
surface and the BAP inserted.  The sampler were programmed and set at 200L.  At the end of 
the cycle, the agar plate was removed and the disinfecting procedure repeated.  The following 
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procedures and protocol to collect air samples were established and followed during the pilot 
study: 
 
Two air samples were taken at the selected bedsides where nebuliser samples were taken.  
The SAS sampler was positioned on the trolley no more than one meter away from the 
ventilator at the bedside.   An aseptic procedure was followed at all times.  The program was 
selected at 200 L. The procedure was repeated to collect two sets of air samples.   Each BAP 
was coded and the time and date was documented.  After collecting the nebulisers and air 
samples, each BAP was put in a zip lock bag and stored upside down in a cooler box for safe 
transportation to the PML at the Wits University and to prevent fluctuation of temperature. 
Cooler boxes were utilized during transportation to keep temperature constant.  Microbial 
cultures remain dormant in cooler temperatures and thus kept in this manner until incubations 
were undertaken.  The trolley was cleaned and the swabs, gloves, apron and gauze were 
discarded before the next assessment commenced. 
 
Four BAPs were collected at each bed side, two air samples and two nebuliser samples. All 
samples were stored upside down in a cooler box and transported by car to the PML for 
incubation.  One air BAP and one nebuliser BAP were incubated for 25°C for seven days for 
possible fungal contamination and the other BAPs incubated for 37°C for 24h for possible 
bacterial contamination.  These BAP were placed upside down in the incubator and time and 
date were documented.  
 
After incubation the plates were removed and the BAPs assessed with the assistance of an 
expert in microbiology for fungal and bacterial growth. The BAP (Figure 3.3) were assessed 
according to the number of colony forming units (CFU) and each colony was described 
according to elevation, colour, shape, size, surface, margins, density, pigments and the 
presence of haemolysis. The data collected during the pilot study were not included in the final 
results.   
 
35 
 
 
 
 
 Figure 3.3:   Blood Agar Plate with Colonies 
 
3.5.3 Application of the Audit Tools 
The audit tool used by Ellis et al (2013) was reviewed and adapted according to the objectives 
for this study. The content of the revised audit tool was reviewed by two senior researchers 
prior to its use in the study. Audit tools were completed during the pilot study to practice the 
collection of information from the environment and patients’ charts.  
 
The audit tool used to collect information consisted of two parts (Appendix 6). The first related 
to the collection of the demographic data (Section A) of the unit and the second related to the 
individual assessment (Section B) of each nebuliser selected according to the inclusion criteria.  
Section A included information regarding the type of ICU, number of beds in the unit, number 
of   ventilated patients and those receiving nebulisation. The last part of Section A consisted of 
information regarding the protocol of decontamination of the unit and the method that was used 
to store the nebulisers.  Any additional observations that were made during assessment were 
also documented. 
 
Section B included information regarding the type of nebuliser, the manufacturer, single 
use/single patient use/autoclave, medication used for nebulisation, the days of nebuliser use 
and usage per day.  The second part consisted of collecting information regarding the 
environment at the bed side and the method used to store the nebulisers.  Visual inspection of 
each nebuliser was done to document the presence of contamination.  Observations of the 
environment were also made and included the presence of windows, type of light, isolation 
cubicle and blinds.  The methods used to store nebulisers were documented (e.g., open to 
environment, gloves, paper bag, sterile cloth and oxygen connection). 
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The time of assessment and additional observations of the environment were documented for 
e.g. if the patient was isolated and the various air filtering systems for each ICU.  The 
additional information collected from the environment were not included in the final results.  
There were no discrepancies found regarding the methods of sample collection.  During the 
pilot study the routine of the procedures were established and documented. 
 
3.6 DATA COLLECTION  
3.6.1 Completion of Section A of the audit tool with Unit Manager/Shift Leader 
The unit manager or shift leader of the ICU was asked questions in order to complete Section 
A of the audit tool on the day of audit.  Thereafter the unit manager/shift leader identified the 
beds in the unit of   patients receiving MV.  The unit manager/shift leader assisted in identifying 
nebulisers at the bedsides of patients in the ICU which was then listed for assessment. 
 
3.6.2 Assessment of Nebuliser and Environment 
The second part of the audit tool (Section B) was completed for nebulisers at the bed sides of 
patients that were identified by the unit manager for assessment.  The nurse at the bedside 
was approached to discuss the nature of the study and to answer any questions arising from 
the discussion. The researcher ensured that the research procedure did not interfere in the 
patient’s care at the time of audit. The first part of Section B was completed by gathering 
information from the ICU chart or with the assistance of the nurse.  The second part consisted 
of observations made regarding the environment and the nebuliser at the bed. 
 
3.6.3 Collection of Nebuliser and Air Samples 
Nebuliser swabbing and air samples were done by following the protocols established and 
practiced through the pilot study mentioned above.     
 
3.7 ASSESMENT AND IDENTIFICATION PROCEDURE 
The BAPs were assessed for fungal and bacterial growth after the incubation time was 
completed as practiced at the PML.  All information collected during the assessment of each 
BAPs was written up on a Microsoft Excel spreadsheet and filed. Similar colonies cultured from 
the air samples and nebulisers were grouped according to their visual description for each 
hospital.  The most frequently observed colonies which were similar and identified in both 
nebuliser and air samples for each hospital were documented.  
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The five most frequently observed colonies cultured from the air as well as nebuliser for each 
hospital were identified and selected for identification. These colonies were streaked across 
Tryptone soya agar (TSA) for identification.  These plates were pre-prepared at the PML at 
Wits University. 
3.7.1 Streaking Method on TSA for Identification 
Bacterial colonies grown on BAPs (Figure 3.4) were streaked on TSA for further identification 
under supervision at PML.  A sterile petri dish with TSA was labelled at the bottom before 
streaking was done.  The Bunsen burner was used to flame the inoculating loop to redness.  
After the loop was cooled down a loopful of colony was streaked on the petri dish from side to 
side in parallel lines similar to the method used for streaking the BAP.  These plates were 
incubated for 37°C for 24 hours and stored upside down in steel baskets in the fridge.  API 
strips were used to assist in identification of micro-organisms (higher concentration of bacteria 
as well as CFU).  Figure 3.5 is a diagrammatic representation of the processed followed during 
the data collection period. 
 
 
 
 
 
 
 
 
                                 Bacterial colonies on BAPs of Micro Mist small volume Nebulisers 
 
 
 
                                   
              
 
 
 
 
                                   Fungal colonies on BAPs of Micro Mist small volume Nebulisers 
 
 
 
 
 
 
 
 
 
Bacterial colonies on BAPs of Aeroneb Nebulisers 
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Fungal colonies on BAPS of Aeroneb Nebulisers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                  
                                Bacterial colonies on BAPs of Air Samples 
 
 
 
 
 
 
 
 
Fungal colonies on BAPs of Air Samples 
 
Figure 3.4: Colonies on BAPs of Nebulisers and Air Samples 
 
 3.8 DATA ANALYSIS 
Descriptive statistics was used to analyse data relating to ICU and nebuliser 
demographics.  Demographic information described by categorical data such as nebuliser 
type, aerosol medication and nebuliser dose was summarized using numbers and 
percentages.  Descriptive statistics relating to days and frequency of nebuliser use was 
summarized by using means and standard deviation.  The Fischer exact test was used to 
ascertain the association of contamination of the Micro Mist small volume nebuliser to the 
following variables:  stored wet, stored in a glove, stored under a glove and open to the 
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environment. Statistical significance was set at 5% (p-value < 0.05) for all inferential statistics. 
Percentages and numbers were used to describe the association of nebuliser contamination 
with different storage and decontamination practices.  This information is included in the text 
and presented in graphs and tables.  Data analysis was conducted using IBM SPSS 22 and 
Stata13.1.  Data from the participating hospitals were pooled together in one data set and 
analysed as such to maintain hospital anonymity. 
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Figure 3.5:  A Diagrammatic Representation of the Processes Followed During the 
Data Collection Period     
Obtaining consent from the Hospital Manager/Chief 
Executive Manager/Infection Control Manager 
Obtaining consent from the Unit 
Manager of each ICU 
Interview with the Unit managers 
Four private hospitals 
Seven ICUs 
Beds screened = 440 
Patients receiving MV = 132 
Patients receiving aerosol therapy = 92 
Beds selected and sampled = 61 
Hospital 1  
Beds sampled 12 
Hospital 2 
Beds sampled 12 
Hospital 3 
Beds sampled 32 
Hospital 4 
Beds sampled 5 
61 BAP sampled from nebulisers 
for bacterial contamination 
61 BAP sampled from the 
surrounding air for fungal 
contamination 
61 BAP sampled from the 
surrounding air for bacterial 
contamination 
61 BAP sampled from nebulisers 
for fungal contamination 
Selected bacterial samples streaked on TSA 
for identification 
37 Micro Mist small 
volume nebulisers 
24 Aeroneb 
nebulisers 
Data collection period: 
 27 days  
Samples taken at each bed side: 2 nebuliser and 2 air samples 
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CHAPTER 4 
4. RESULTS 
 
4.1 INTRODUCTION 
This chapter presents the results obtained through data collected from both audit tools and 
samples taken.  This includes information collected through visual inspection of the nebuliser, 
the storage method of the nebuliser and the surrounding ICU environment.  Storage and 
decontamination protocols for each ICU were obtained by completing Section A of the audit 
tool with the unit manager.  The type of aerosol medication and the frequency of application of 
this medication through the nebuliser was obtained from the patient’s chart.   
 
Consent was obtained from four private hospitals in Pretoria.  Seven ICUs within these 
hospitals were selected for sampling.  The types of ICUs included in the study were: cardiac 
care, medical, surgical, trauma, neurology and mixed units.  A total of 440 beds were screened 
in the seven ICUs.  Of these beds 132 (30.0%) patients received MV and 92 (69.7%) aerosol 
therapy.  A total of 61 nebulisers and their surrounding air were sampled.  The total nebuliser 
sample included 24 Aeroneb and 37 Micro Mist small volume nebulisers. The remaining 
nebulisers and their surrounding air were not sampled due to isolation of the patients and the 
risks of cross-infection or time constraints.  Due to isolation of patients, the number of beds in 
the ICUs selected changed during the course of data collection. 
 
The results obtained in this study will be discussed in line with the research objectives outlined 
in Chapter one.     
 
4.2 THE TYPES OF NEBULISERS AND MEDICATION USED FOR AEROSOL THERAPY IN 
ICUs OF HOSPITALS IN PRETORIA  
 
Two types of nebulisers were identified in the four hospitals during the study, namely the 
Aeroneb nebuliser, a new addition to the ventilator circuit and the Micro Mist small volume 
nebuliser. The Aerosol Tee connector that forms part of Micro Mist small nebuliser was the 
only type of Tee connector identified in the ICUs in Pretoria. Figure 4.1 provides information on 
the nebuliser types identified in the four hospitals.     
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Figure 4.1: Nebuliser Types Identified in the Four Hospitals 
 
In hospital one only the Micro Mist small volume nebuliser was used. In hospital two only the 
Micro Mist small volume nebuliser was sampled although both nebulisers were used.  In 
hospital two the Aeroneb nebuliser was used to a lesser extent and only one was observed 
during the data collection period.  In hospital three both devices were in use. In hospital four 
only Aeroneb nebulisers were sampled although both types of nebulisers were used to 
administer aerosol medication. 
 
Figure 4.2 represents the different ICUs where the two types of nebulisers were sampled.  The 
eight units represent different types of ICUs.  Unit zero represents the cardiac ICU, unit one the 
medical ICU, unit two the surgical ICU, unit 3 the surgical and trauma ICU, unit four the trauma 
and neurology ICU, unit five the mixed ICU, unit six the surgical and medical ICU and unit 
seven the cardiac and surgical ICU.  The mixed ICU [unit 5] used the most Aeroneb (n=11) and 
Micro Mist small volume nebulisers (n=17) when administering aerosol medication. 
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Figure 4.2:  Type of Nebulisers in the Different ICUs 
 
Four types of aerosol medication were identified namely, bronchodilators (e.g. Atrovent,   
Ventolin), corticosteroids (e.g. Pulmicort), saline (0.9%) and mucolytics (e.g. Bisolvon).  Figure 
4.3 provides information regarding aerosol medications used in the ICUs.        
                       
 
Figure 4.3:  Types of Aerosol Medication 
 
  
1 1 
3 
11 
1 
7 
3 
2 2 
17 
7 
6 
0
2
4
6
8
10
12
14
16
18
Unit 0 Unit 1 Unit 2 Unit 3 Unit 4 Unit 5 Unit 6 Unit 7
N
u
m
b
e
r 
o
f 
n
e
b
u
lis
e
rs
 
Type of ICU 
Aeroneb nebuliser Micro Mist small volume nebuliser
22 
14 
2 
23 
2 
8 
14 
Bronchodilators Mucolytics other than
saline
Corticosteroids Saline
N
u
m
b
er
 o
f 
n
eb
u
lis
er
s 
Aeroneb nebuliser
Micro Mist small volume nebuliser
44 
 
 
 
The aerosol medication mostly used in the ICUs was bronchodilators (n=45) and mode of 
application was similar (Aeroneb, n=22 and Micro Mist, n=23). The aerosol medication least 
used was mucolytics (n=2) other than saline. Saline aerosolisation was usually used with 
physiotherapy treatments (n=16) and the mode of application was mainly the Micro Mist small 
volume nebuliser.   
 
Bronchodilators in order mostly used were; Combivent, Atrovent, Duolin and Ventolin.  
Pulmicort was the only corticosteroid used for aerosolisation and Bisolvon the only mucolytic 
other than saline. Pulmicort was also mainly used in conjunction with bronchodilators.  The four 
types of aerosol medication used for aerosolisation are displayed according to their application 
in the eight types of units in Figure 4.4. 
 
 
 
 
F
igure 
4.4: 
 
Aero
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Medi
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n 
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in the Different ICUs 
 
Bronchodilation therapy was used the most across all units and with higher frequencies noted 
in the mixed ICU (n=20) [unit 5], cardiac and surgical ICU (n=8) [unit 7] and lastly the surgical 
and medical ICU (n=6) [unit 6]. Corticosteroid therapy was the most used in the mixed ICU 
(n=9) [unit 5].  Saline administration as aerosol medication was the second most frequently 
used across ICUs as it was in use by six units.  Mucolytic therapy (n=2) was only in use in the 
cardiac and surgical ICU [unit 7].    
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4.3 DAILY APPLICATION OF NEBULISERS IN THE ICU 
The nebuliser dose describes the frequency of daily application and is illustrated in Figure 4.5.  
Eleven categories of nebuliser dose were identified.  Categories that consisted of two time 
periods were due to two types of aerosol medications used within the nebuliser at different time 
intervals.  The categories are as follows:  zero:  four hourly, one: as needed, two: six hourly, 
three: twice a day, four: eight hourly, five: twice a day and four hourly, six: six and eight hourly, 
seven: four and six hourly, eight: four and eight hourly, nine: two and three hourly, ten: eight 
and twelve hourly, eleven: six and twelve hourly.   
 
 
    Figure 4.5:  Aerosolisation Dosage for the Two Types of Nebulisers 
 
The most frequently used dose to administer aerosol medication was a dose of six hourly 
(n=25) [category two] with the Aeroneb in use the most (n=14) and the Micro Mist less (n=11) 
in use in this dose category. The second most frequently prescribed dose was four hourly 
(n=9) as depicted by category zero. 
 
Table 4.1 provides information regarding the mean number of days the different types of 
nebulisers were used as well as the mean number of aerosolisation sessions. 
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Table 4.1:  Nebuliser Days and Aerosolisation Sessions 
 
 
 
 
 
 
 
 
   
The mean number of days that the Aeroneb nebuliser was in use was 15.0 (±14.6) days and 
the mean number of aerosolisation sessions 75 (±74.9). The mean number of days the Micro 
Mist small volume nebuliser was in use was 11.6 (±13.9) and the mean number of 
aerosolisation sessions 56.2 (±90.1). 
 
Six of the Micro Mist small volume nebulisers was used for more than 90 aerosolisation 
sessions and three Micro Mist small volume nebulisers was used for more than 30 days. 
 
4.4 DECONTAMINATION PROTOCOLS AND STORAGE PRACTICES OF NEBULISERS IN 
THE ICUs 
 
Six decontamination storage protocols were identified in the seven ICUs during the course of 
the study.  A summary of the protocol is given in Table 4.2. 
 
The ICU in hospital one had a decontamination storage protocol [protocol one], hospital two 
had two ICUs and both had the same protocol for decontamination and storage [protocol two].  
Hospital three had two ICUs with different decontamination and storage protocols [protocol 
three and four] and hospital four had two ICUs with different decontamination protocols but the 
same storage protocol [protocol five and six].   
 
None of the Micro Mist small volume nebulisers were discarded after use.  All methods for 
decontamination differed in the type of rinsing solution used.  Three types of rinsing solutions 
were identified namely, 70% alcohol, wash with bioscrub and sterile water.  Most protocols 
stated that the Micro Mist small volume nebulisers be dried with a paper towel (n=4).  Only one 
protocol had no method of decontamination however, nebulisers were being dried with a paper 
Type of Nebulisers n Minimum Maximum Mean ±SD 
Aeroneb 24     
Nebuliser days 24 2.0 66.0 15.0 ±14.6 
Aerosolisation sessions 24 8.0 264.0 75 ±74.9 
 
Micro Mist 37     
Nebuliser days 37 1.0 62.0 11.6 ±13.9 
Aerosolisation sessions 37 2.0 496.0 56.2 ±90.1 
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towel after use.  Decontamination protocols differed between ICUs, and between the two ICUs 
within Hospital three.  There were no decontamination and storage protocols reported by the 
unit managers for the Aeroneb nebuliser.  The Aeroneb nebuliser is developed to remain in the 
ventilator circuit during the period of MV and does not need to be decontaminated or stored 
separately from the MV circuit.  
 
Storage protocol one was the only protocol whereby the Micro Mist small volume nebuliser was 
left open to the environment.  However it was observed that the nebulisers were not stored on 
a hook at the bed side but left open in a petri dish.  Storage protocols four to six stated that the 
Micro Mist small volume nebulisers be stored inside a latex glove while connected to the 
oxygen output of the ventilator.  In protocol two, used in two ICUs, the Micro Mist small volume 
nebulisers were not dried before they were stored under a sterile cloth.  According to the unit 
manager these sterile cloths are replaced every week.   In protocol three the Micro Mist small 
volume nebulisers were stored inside an acceptor bag, however, no acceptor bag was 
observed during data collection in that ICU.  Storage protocols differed between ICUs, and 
between the two ICUs within Hospital three.   
 
Table 4.2: Type of Decontamination and Storage Protocols Reported by Unit 
Managers to be in Place for the Micro Mist small Volume Nebuliser  
Protocol Discarded Rinsed Method of Decontamination 
Dried 
Nebuliser 
Drying Method Method of Storage 
1 No Yes 70 % alcohol Yes Paper towel 
Connected to the  
oxygen output of the 
ventilator,  stored on 
a hook at the bed 
side and open to the 
environment 
2 No Yes Provac water No None 
Connected to 
oxygen, taken apart 
and left to dry under 
a sterile cloth 
3 No Yes 
Wash with bioscrub once a  
day 
Yes Paper towel 
Stored in 
acceptor(sterile) bag 
4 No No  None Yes Paper towel 
Stored in a glove 
connected to the 
oxygen output 
5 No Yes Saline of Sterile water No  None 
Stored in a glove 
connected to the 
oxygen output 
6 No Yes 
Wash with bioscrub after 
aerosolisation 
Yes Paper towel 
Stored in a glove 
connected to the 
oxygen output 
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4.5 THE INCIDENCE OF CONTAMINATION OF NEBULISERS AFTER USE WITHIN A 
VENTILATOR CIRCUIT 
A total of 61 nebuliser samples were collected and a total of 31 (50.8%) nebuliser swabs 
presented with contamination.  The incidence of contamination of both types of nebulisers was 
similar: Micro Mist small volume (n=19; 51.4%) and Aeroneb (n=12; 50%).  Figure 4.6 
illustrates the incidence of contamination of the Micro Mist small volume nebulisers. 
 
 A total of 37 Micro Mist small volume nebulisers were included in this study.  A combination of 
bacterial and fungal growth was seen the most in the Micro Mist small volume nebulisers 
(n=11; 29.7%). The total fungal growth (n=17) were more than the total bacterial growth (n=13) 
in the Micro Mist small volume nebulisers. 
 
 
 
Figure 4.6: Incidence of Contamination of the Micro Mist small Volume Nebuliser 
 
Figure 4.7 provides information regarding the incidence of contamination of the Aeroneb 
nebulisers. A total of 24 Aeroneb nebulisers were included in this study.  A combination of 
bacterial and fungal growth (n=9; 37.5%) was mostly observed. The total bacterial growth 
(n=11) was almost similar to the total fungal growth (n=10) in the Aeroneb nebulisers.  
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Figure 4.7: Incidence of contamination of the Aeroneb Nebuliser 
 
The following figures present the incidence of contamination found in the different nebulisers in 
the four hospitals. 
 
Hospital One 
A total of 12 Micro Mist small volume nebuliser swabs were collected in Hospital one.  The 
incidence of contamination in the Micro Mist small volume nebulisers in this hospital is shown 
in Figure 4.8.  Only three Micro Mist small volume nebulisers (n=3; 25%) presented with 
contamination in Hospital one with an even distribution of bacterial (n=1), fungal (n=1) and 
bacterial and fungal (n=1) contamination.  
 
Hospital Two 
A total of 12 Micro Mist small volume nebuliser swabs were collected in hospital two.  The 
incidence of contamination in the Micro Mist small volume nebuliser in this hospital is shown in 
Figure 4.9.  In Hospital two, eight (66.7%) Micro Mist small volume nebulisers presented with 
bacterial and fungal growth (n=4; 33.3%). 
 
Hospital Three 
A total of 32 nebuliser swabs which includes, Aeronebs (n=19) and Micro Mist small volume 
nebulisers (n=13) were collected in Hospital three.  The incidence of contamination of 
nebulisers in this hospital is shown in Figure 4.10 and 4.11.  Eight (61.5%) Micro Mist small 
volume nebulisers in hospital three presented with contamination of which a combination of 
bacterial and fungal growth (n=6; 46.2%) was mostly observed.  The total fungal growth (n=8) 
was more than the total bacterial growth (n=6) in the Micro Mist small volume nebulisers.  Less 
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contamination was observed in the Aeroneb nebulisers in Hospital three, with nine (47.4%) 
nebulisers presenting growth where a combination of bacterial and fungal contaminants (n=6; 
31.6%) were observed.  The total bacterial growth (n=8) was more than the total fungal growth 
(n=7) in the Aeroneb nebulisers. 
 
Hospital Four 
A total of five Aeroneb nebuliser swabs were collected in Hospital four.  The incidence of 
contamination of nebulisers in this hospital is shown in Figure 4.12. Three (60%) Aeroneb 
nebulisers presented with bacterial and fungal contamination (n=3).  
 
Hospital two presented with the most contamination in the Micro Mist small volume nebulisers 
(66.7%) and Hospital four with the most Aeroneb contamination (60%). 
                  
Figure 4.8:  Incidence of contamination   Figure 4.9: Incidence of contamination  
                    in Hospital One                       in Hospital Two 
                                                   
Figure 4.10:  Incidence of contamination in Figure 4.11:  Incidence of contamination     
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Figure 4.12:  Incidence of Contamination in Hospital Four 
 
A summary of the incidence of bacterial contamination in the different types of units found in 
both nebulisers is described in Figure 4.13.   Unit zero represents the cardiac ICU, unit one the 
medical ICU, unit two the surgical ICU, unit 3 the surgical and trauma ICU, unit four the trauma 
and neurology ICU, unit five the mixed ICU, unit six the surgical and medical ICU and unit 
seven the cardiac and surgical ICU.  
 
Bacterial contamination of nebulisers were mostly observed in the mixed ICU (n=10) [unit five] 
and secondly in the surgical and medical ICU (n=5) [unit six]. No bacterial contamination of 
nebulisers was observed in the surgical ICU [unit two] and the trauma and neurology ICU [unit 
four]. 
 
    
Figure 4.13: Bacterial Contamination According to Unit Type 
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A summary of the incidence of fungal contamination in the different types of units found in both 
nebulisers is described in Figure 4.14.  The highest number of fungal contamination of 
nebulisers was observed in the mixed ICU (n=10) [unit 5] and secondly in the surgical and 
medical ICU (n=5) [unit 6]. No fungal contamination of nebulisers was observed in the surgical 
ICU [unit two]. 
 
             
  Figure 4.14: Fungal Contamination According to Unit Type 
 
Ten of the 24 Aeronebs and 17 of the 37 Micro Mist small volume nebulisers presented with 
fungal contamination which can be divided into moulds and yeasts. These findings are 
presented in Figure 4.15.  The nebulisers presented with yeast contamination were mostly 
observed in both Aeroneb (7/24; 29.2%) and Hudson Micro Mist small volume nebulisers 
(15/37; 40.5%).  Less contamination with moulds and a combination of moulds and yeasts 
were observed in both Aeronebs and Micro Mist small volume nebulisers.   
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Figure 4.15: Incidence of Fungal Growth in Micro Mist small volume and Aeroneb 
Nebulisers  
 
4.6     DECONTAMINATION AND STORAGE PROTOCOLS ASSOCIATED WITH BACTERIAL 
GROWTH 
 
The type of decontamination and storage protocols for the Micro Mist small volume nebulisers 
associated with contamination, is illustrated in Figure 4.16.  These protocols are outlined in 
section 4.3.  Only protocol one to four is illustrated in Figure 4.16.  Protocol five and six were 
not illustrated as no Micro Mist small nebulisers were swabbed in the ICUs where these 
protocols were implemented. 
 
When Protocol one was followed the least amount of contamination was found (n=3; 25%).  
Protocol three resulted in the most contamination (n=4; 80%).  Protocol two resulted in the 
most fungal contamination (n=3; 25%).   
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Figure 4.16: Bacterial and Fungal Contamination of Micro Mist small volume 
Nebulisers Associated with Decontamination and Storage Protocols 
 
The following incidence of contamination was observed with different rinsing solutions and 
drying   methods as part of the decontamination storage protocols reported by the unit 
managers. 
 
4.6.1 Rinsing Solutions 
Three types of rinsing solutions were identified in the decontamination protocols.  Solution one:  
70% alcohol; solution two:  sterile water and solution three:  washed with bioscrub. Solution 
one resulted in the least bacterial contamination of Micro Mist small volume nebuliser (n=2; 
16.7%) and solution three resulted in the most bacterial contamination (n=3; 75%).  Solution 
two resulted in bacterial contamination of (n=5; 41.7%) and  using no rinsing solution, resulted 
in three out of the nine nebulisers presenting with bacterial contamination (33.3%).  Solution 
one resulted in the least fungal contamination of the Micro Mist small volume nebulisers (n=2; 
16.7%) and solution three resulted in the most fungal contamination (n=4; 100%).  Solution two 
resulted in fungal contamination of (n=7; 58.3%) and using no rinsing solution, resulted in four 
out of the nine Micro Mist small volume nebulisers with fungal contamination (n=4; 44.4%).  
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4.6.2 Drying Methods 
Two different methods were used to dry the Micro Mist small volume nebulisers as part of the 
decontamination protocols and are as follows, method one: dry the nebuliser with a paper 
towel; method two:  take the nebuliser apart and leave to dry under a sterile cloth.  Method two 
resulted in the most bacterial contamination (n=5; 41.6%) and fungal contamination (n=7; 
58.3%).  Method one resulted in the least bacterial contamination (n=8; 32%) and fungal 
contamination (n=10; 40.0%). 
 
4.6.3 Storage Methods 
Four types of storage methods were evaluated during visual inspection on the day of audit and 
are as follows: method one: stored in a glove; method two: stored under a sterile cloth; method 
three:  stored open to the environment and method four: stored in a paper bag.  Most Micro 
Mist small volume nebulisers were stored in a latex glove (n=20).  More than a third of the 
Micro Mist small volume nebulisers, stored in a glove presented with bacterial growth (n=7; 
35%) and half with fungal contamination (n=9; 47,4%).  Since the p-value is 0.717 (>0.05), 
there is evidence of no relationship (association) between method one and bacterial growth. 
 
Method two resulted in the most bacterial contamination (n=4; 44.4%) and the most fungal 
contamination (n=6; 66.7%).  Since the p-value is 0.624 (>0.05), there is evidence of no 
relationship (association) between method two and bacterial growth. 
 
Method three resulted in the least bacterial (n=2; 28.6%) and fungal contamination (n=2; 
28.6%).  No paper bags were observed during the sampling procedures.  Since the p-value is 
0.594 (>0.05), there is evidence of no relationship (association) between method three and 
bacterial growth. 
 
One nebuliser was left in the ventilator circuit and presented with fungal contamination and no 
bacterial contamination.  Five Micro Mist small volume nebulisers were stored connected to the 
oxygen port of the ventilator.  Only one presented with bacterial and fungal contamination (n=1; 
20%). 
 
4.6.4 Aerosol Medication 
Contamination associated with aerosol medication used in the Micro Mist small volume and 
Aeroneb nebulisers were observed.  Bronchodilators were mostly used for aerosol nebulisation 
in Micro Mist small volume nebulisers followed by saline, corticosteroid and mucolytics (other 
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than saline).  Bronchodilators were also mostly used in Aeroneb nebulisers followed by 
corticosteroid and saline.  No mucolytics were used in Aeroneb nebulisers. The highest 
bacterial contamination was found in Micro Mist small volume (n=4; 50%) and Aeroneb 
nebulisers (n=8; 57.1%) associated with corticosteroids aerosolisation. Bronchodilator 
aerosolisation was associated with (n=9; 39.1%) contamination in the Micro Mist small volume 
nebuliser and (n=10; 45.5%) in the Aeroneb nebuliser.  Saline inhalation was associated with 
(n=5; 35.7%) bacterial contamination. No contamination was found in Micro Mist small volume 
nebulisers used for mucolytics (n=2; 0%).  No contamination was found in Aeroneb nebulisers 
used for saline aerosolisation. 
 
4.6.5    Wet and Dry Chambers 
Visual inspection of each nebuliser on the day of audit was performed to establish if the 
chambers were stored wet or dry. In this study a nebuliser was described as “wet” when fluid 
was observed in base of the chamber and the inner surface of the chamber. The results 
obtained through visual inspection of the Micro Mist small volume nebuliser is illustrated in 
Figure 4.17.  
 
4.6.5.1 Micro mist small volume nebuliser  
Most of the Micro Mist small volume nebulisers were stored wet (n=33; 89.2%).  Only four 
nebulisers were stored dry (n=4; 10.8%). Bacterial contamination was found in 11 of the 33 wet 
Micro Mist small volume nebulisers (n=11; 33.3%) and fungal contamination found in 16 (n=16; 
48.5%). One dry Micro Mist small volume nebuliser presented with (n=1; 25%) bacterial and 
(n=1; 25%) fungal contamination. Three out of the four dry Micro Mist small volume nebulisers 
presented with no contamination (n=3; 75%). One species was identified in seven wet Micro 
Mist small volume nebulisers (7/11) and in one dry Micro Mist small volume nebuliser (1/4).  
Two species were identified in three nebulisers (3/11) and three species in one nebuliser 
(1/11).  Most of the wet Micro Mist small volume nebulisers presented with more than 50 
colonies (6/11) as well as one dry nebuliser (1/4).  Two Micro Mist small volume nebulisers 
presented with colonies between one and 10 (2/11) and two nebulisers with colonies between 
21 and 30 (2/11).  Although the odds ratio (0.67 and 95% Constant Interval = 0 – 5.42) shows 
a 33% reduced risk of bacterial growth in dried as compared to wet nebulisers, there is 
evidence of no association between dryness of the nebuliser chamber and bacterial growth (p-
value=0.7367) because the p-value is not significant.   
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Three out of the six Micro Mist small volume nebulisers that was used for more than 90 
aerosolisation sessions presented with both bacterial and fungal contamination (50%).  Nine 
out of the 31 Micro Mist small volume nebulisers used for less than 90 sessions presented with 
bacterial contamination (29%) and eleven with fungal contamination (35.5%). 
 
 
Figure 4.17: Visual Inspection of the Micro Mist small volume Nebuliser 
 
4.6.5.2 Aeroneb nebuliser 
The results obtained through visual inspection of the Aeroneb nebuliser are illustrated in Figure 
4.18.  Most of the Aeroneb nebulisers were found to be wet with visual inspection (n=20; 
83.3%).   
Only four were dry (n=4; 16.7%). Bacterial contamination was found in 10 of the 20 wet 
Aeroneb nebulisers (n=10; 50%) and in one dry nebuliser (n=1; 25%).  Fungal contamination 
was found in 8 of the 20 wet Aeroneb nebulisers (n=8; 40%) and two dry nebulisers (n=2; 
50%).  One species was identified in all the wet Aeroneb nebulisers (10/10) and in one dry 
nebuliser (1/4). Colonies between one and 10 were identified in six wet Aeroneb nebulisers 
(6/10) and more than 50 colonies were identified in three wet Aeroneb nebulisers (3/10) and in 
one dry nebuliser (1/10).  
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        Figure 4.18:  Visual Inspection of the Aeroneb Nebuliser 
 
4.7 BACTERIAL MICRO-ORGANISMS IDENTIFIED IN CONTAMINATED NEBULISERS AND 
SURROUNDING AIR 
 
Ten types of micro-organisms were identified in the nebulisers and surrounding air.  This is 
shown in Figure 4.19.  Micro-organisms were identified in 19 air samples, six Micro Mist small 
nebuliser and seven Aeroneb nebuliser samples. The different micro-organisms included; 
Enterococcus spp., Coagulase-negative Staphylococcus spp., Staphylococcus aureus, 
Neisseria spp.; Bacillus spp., Micrococcus and related species, Pseudomonas stutzeri, 
Brevundimonas vesicularis, Empedobacter (F.) brevis and Stenotrophomonas spp. 
 
Coagulase-negative Staphylococcus was identified the most in air samples (n=8; 42.1%) 
followed by Pseudomonas Stutzeri (n=4; 21.1%) and Neisseria spp. (n=3; 15.8%).  Coagulase-
negative Staphylococcus (CoNS) was also the most identified in Aeroneb nebulisers (n=4; 
57.1%).  Enterococcus spp. was the most identified in Micro Mist small volume nebulisers 
(n=2; 33.3%) and also identified in all three types of samples. 
 
The micro-organisms identified in the samples included seven contaminated nebulisers and 
their corresponding air samples.  The same bacterial micro-organisms were identified in two 
nebulisers and their corresponding air samples (n=2; 28.6%).  An Enterococcus sp. was 
identified in one Micro Mist small volume nebuliser and its corresponding air sample and a 
Coagulase-negative Staphylococcus sp. was identified in one Aeroneb nebuliser and its 
corresponding air sample.  
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A=Enterococcus spp., B=Coagulase-negative Staphylococcus spp., C=Staphylococcus 
aureus, D=Neisseria spp.; E=Bacillus spp., F=Micrococcus and related species, 
G=Pseudomonas stutzeri, H=Brevundimonas vesicularis, I=Empedobacter (F.) brevis,  
J=Stenotrophomonas spp.  
Figure 4.19: Bacterial Micro-organisms Identified in Contaminated Nebulisers and Air 
Samples 
 
Figure 4.20 illustrates the bacterial and fungal contamination of the surrounding air where 
these nebulisers were kept. A high incidence of contamination was identified in air samples 
(n=60; 98.4%).  Most of the air samples had bacterial and fungal contamination (n=43; 70.5%) 
followed by fungal contamination (n=12; 19.7%) and bacterial contamination (n=5; 8.2%).  The 
total fungal contamination (n=55; 90.2%) in air samples was higher than the total bacterial 
contamination (n=48; 78.7%).  The various ventilation systems were identified by questioning 
the unit manager in the hospitals and were as follows; Hospital one- HEPA filter; Hospital two- 
Chilled Water Fan Coil Unit and Direct Expansion System; Hospital three -  Air Handling Unit; 
Hospital four-  Chilled Water Fan Coil Unit. 
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    Figure 4.20:   Bacterial and Fungal Contamination in Air Samples  
 
More than two thirds of patients received aerosol therapy during MV.  Bacterial and fungal 
contamination of nebulisers was mostly observed in the mixed ICUs. Although most of the 
protocols in the ICUs included drying of the Micro Mist small nebulisers, most of the Micro Mist 
small volume as well as Aeroneb nebulisers were found to be wet during visual inspection. The 
incidence of bacterial contamination was higher in the wet Aeroneb type nebulisers which are 
manufactured to be left in the ventilator circuit and continuously exposed to ventilator gasses.  
Most of the Micro Mist small volume nebulisers were stored in a latex glove.  Storing Micro Mist 
small volume nebulisers under a sterile cloth resulted in a higher incidence of bacterial and 
fungal contamination.  Rinsing the Micro Mist small volume nebuliser with 70% alcohol before 
storage resulted in the least amount of bacterial contamination. Incidence of contamination of 
the Aeroneb and Micro Mist small volume nebulisers was similar despite different application 
protocol, storage and cleaning methods. 
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CHAPTER 5 
5. DISCUSSION 
 
5.1       INTRODUCTION 
The incidence of contamination as well as the current practice of decontamination and storage 
of nebulisers used within a ventilator circuit in ICUs in Pretoria is unknown.  A similar study 
was done in the ICUs in Johannesburg and the results of that study will be compared with the 
current study to assist in gaining an overall perspective of contamination and nebuliser 
practice in ICUs in Gauteng.  
 
The main finding from the current study was the incidence of bacterial and fungal 
contamination of the Micro Mist small volume nebuliser and the Aeroneb nebuliser when used 
in a ventilator circuit.  The incidence of contamination of the Micro Mist small volume nebuliser 
in this study corresponds with the incidence of contamination found in the same aerosol device 
in ICUs in Johannesburg (Ellis et al., 2013).  The Aeroneb nebuliser is a new device that was 
recently introduced to clinical practice as a means of administration medication to a 
mechanically ventilated patient. No previous research regarding the incidence of contamination 
in the Aeroneb nebuliser could be sourced in the literature.  The incidence of contamination 
found in the Aeroneb nebuliser was similar to the incidence of contamination in the Micro Mist 
small volume nebuliser.  In the current study both of these nebulisers were used as single-
patient use devices which is in contrast to the information reported by Ellis et al. (2013) as the 
Micro Mist small volume nebuliser was reclassified by the manufacturer from single-use to 
single-patient use device.  Secondly, all the ICUs had decontamination and storage protocols 
in place for the Micro Mist small volume nebuliser, however, all of these protocols differed 
between hospitals and different ICUs within the same hospital.  Thirdly, more Micro Mist small 
volume nebulisers that were stored under a sterile drape presented with bacterial 
contamination which corresponds with Ellis et al. (2013) study.  Lastly, almost 90% of Micro 
Mist small volume nebulisers were stored wet.  More than two thirds of ventilated patients, 
received aerosol therapy in the ICUs in Pretoria, which indicated that aerosol therapy was an 
important treatment during MV. This finding is supported by an international survey which 
found that 95% of intensivists prescribe aerosol therapy to patients receiving MV (Ehrmann et 
al., 2013). 
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5.2  THE TYPES OF NEBULISERS AND MEDICATION USED FOR AEROSOL THERAPY IN 
ICUs IN PRETORIA       
 
The Micro Mist small volume nebuliser is a jet nebuliser which connects to a port on the 
ventilator and the Aeroneb nebuliser is a VMN which operates electronically within the 
ventilator circuit.  The Aeroneb nebuliser was not identified as one of the nebulisers used in the 
ICUs in Johannesburg at the time of the study done by Ellis et al. (2013).  The Micro Mist small 
volume nebuliser was mostly used in the ICUs in Pretoria.  This corresponds with Ellis et al. 
(2013) study in ICUs in Johannesburg and an international survey conducted by Erhmann et 
al. (2013).  The Aeroneb nebuliser was used less frequently in the ICUs of hospitals in 
Pretoria.  A factor that could influence its usage might be the cost of this new device as the 
cost is markedly higher than the Micro Mist small volume nebuliser.  The Aeroneb device is 
almost 10 times the cost of the Micro Mist small volume nebuliser.   An international survey by 
Ehrmann et al. (2013) supports this assumption and showed that only 14% of respondents 
used VMN in MV whereby cost was suggested as a limiting factor.  
 
According to the Unit managers in the ICUs that were surveyed, the Aeroneb nebuliser is used 
when a patient requires continuous positive end-expiratory pressure or if a patient is on long 
term ventilation.  This is in contrast to the Micro Mist small volume nebuliser which is used 
more frequently in patients requiring ventilation following surgical procedures who are 
anticipated to be extubated from the ventilator soon.  
 
Most Aeroneb samples were collected in the mixed ICUs.  It could be hypothesized that there 
were more long-term ventilated patients in the mixed ICUs who required aerosol therapy.  A 
report done by the International Nosocomial Infection Control Consortium (INICC) between 
2003 and 2008 supports this hypothesis whereby the average length of stay (LOS) for patients 
in an ICU consisting of mixed conditions e.g. medical and surgical cases was found to be much 
higher than other types of ICUs (INICC, 2010).   
 
Four types of aerosol medication were identified during the course of this study namely, 
bronchodilators, corticosteroids, saline and mucolytics. Bronchodilators were the most frequent 
aerosol medication used for nebulisation in the seven ICUs followed by corticosteroids, saline 
and mucolytics. This corresponds with the study done by Ellis et al. (2013) whereby 
bronchodilators were ranked the highest.  Mucolytics however were the second highest ranked 
medication administered in ICUs in Johannesburg while in Pretoria ICUs these ranked last in 
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the group of aerosol medications. Mucolytics and saline were grouped together in the study 
done by Ellis et al., (2013) and therefore the higher rank of mucolytics.  The mucolytics used in 
the ICUs in Johannesburg were Bisolvon, which was only used in one nebuliser, and saline, 
which was used in eight nebulisers.  In the current study administration of bronchodilators were 
high in both the Micro Mist small volume and Aeroneb nebuliser.  An international survey 
showed similar results whereby bronchodilators were administered the most frequent followed 
by steroids (Erhmann et al., 2013). No antibiotics were used for nebulisation during this study 
while in an international survey antibiotics and especially Colistin were regularly aerolised 
(Ehrmann et al., 2013). Most of respondents in this survey done by Ehrmann et al. (2013) 
worked in an adult mixed ICU setting and reported a positive viewpoint towards inhaled 
antibiotics as an adjunctive or primary treatment method for pulmonary infections.   
 
 5.3 DAILY APPLICATION OF NEBULISERS IN THE ICU  
The Micro Mist small volume nebuliser and the Aeroneb nebuliser are single-patient use 
devices which indicate that they should be used on the same patient for a period of time 
according to the manufacturer’s recommendations. The six hourly (four times a day) 
aerosolisation of medication were used the most in both Aeroneb and Micro Mist small volume 
nebulisers. Information regarding nebuliser dose and the date when aerosolisation 
commenced were collected from the patient’s prescription chart or physiotherapy notes to 
calculate the number of aerosolisation sessions over a period of time.  The mean number of 
days as well as the number of aerosolisation sessions that the Micro Mist small volume 
nebuliser was used, was less than that of the Aeroneb nebuliser.  The Micro Mist small volume 
nebuliser can be used three times a day for 30 days which calculates to 90 aerosolisation 
sessions (SMLT, 2000).  Allen et al. (2005) also recommended that the Micro Mist small 
volume nebuliser should be replaced every 24h if the patient had a respiratory infection.  In the 
current study, the mean number of aerosolisation sessions 56.2 (±90.1) and days 11.6 (±13.9) 
in which the Micro Mist small volume nebuliser was used, was in accordance with what is 
recommended by the SMLT (SMLT, 2000).  Only six of the Micro Mist small volume nebulisers 
were used for more than 90 aerosolisation sessions and three for more than 30 days.  No 
recent literature could be sourced regarding the frequency in which the Micro Mist small 
volume nebuliser is used in South Africa or internationally.  Replacing the Micro Mist small 
volume nebuliser could be costly and time consuming.  The Valved Neb Tee, is a different type 
of Tee connector manufactured by Hudson RCI that is a single-patient use device and can be 
left in the ventilator circuit when the nebuliser is removed.  A valve in the Neb Tee connector 
opens/closes upon insertion/removal of the nebuliser.  The valve prevents loss of ventilation 
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pressure and the release of patient’s aerosols in the surrounding environment (Teleflex, 2014). 
This could result in lower costs and less time spend to remove the Micro Mist small volume 
nebuliser from the circuit.  The Aeroneb nebuliser in contrast is left in the ventilator circuit and 
can be set on an intermittent or continuous cycle.  There is no specified limit to the frequency 
with which the Aeroneb nebuliser may be used (Aerogen, 2014).  
 
During this study no documentation could be found on the ICU cardex or in the patient files to 
indicate how long the Micro Mist small volume nebuliser were in use or if it was replaced.  The 
study design didn’t allow interviews with nursing staff at the bed side and therefore the 
researcher speculates that the ICU personnel were not informed regarding the preferred 
application of the Micro Mist small volume nebuliser and/or Tee connector. 
 
5.4 DECONTAMINATION PROTOCOLS AND STORAGE PRACTICES IN THE ICUS 
Six different decontamination and storage protocols for the Micro Mist small volume nebuliser 
were identified in the seven ICUs assessed in Pretoria.  In contrast, none of the ICUs assessed 
in Johannesburg had nebuliser decontamination and storage protocols in place, however, 
different methods of storage were observed by Ellis et al. (2013).  In the current study the 
decontamination and storage protocols for the Micro Mist small volume nebulisers differed 
between hospitals and between ICUs within the same hospitals in Pretoria.  The researcher 
speculated that the ICU staff were not aware of the manufacturer’s recommendations regarding 
decontamination and storage of the Micro Mist small volume nebuliser.  There were no 
decontamination and storage protocols found for the Aeroneb nebuliser in the ICUs of hospitals 
in Pretoria. The Aeroneb nebuliser is manufactured to be left in the ventilator circuit during the 
period of MV.  The Aeroneb Pro-X controller is for re-use and should be cleaned between 
patients according to the manufacturer’s recommendations (Aerogen, 2014)  
 
Staff nurses at the patient’s bed side where nebuliser sampling was done were not asked 
specifically if they were aware of these protocols and if they applied the protocols.  No clinical 
documentation was found at the bed side regarding the application of a decontamination 
protocol of the Micro Mist small volume nebuliser after each aerosolisation in the ICUs in 
Pretoria.  Different manufacturers have slightly different approaches in cleaning methods but 
all state that washing and drying should be done after each use (Allen et al., 2005). 
 
Three types of rinsing solutions were identified in the six decontamination protocols namely, 
70% alcohol, sterile water and bioscrub.  A cleaning protocol for nebulisers developed by 
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Jadhav et al. (2013) included hand hygiene, washing the nebuliser with soap and distilled 
water and lastly cleaning it with 70% alcohol.  This protocol was followed after high rates of 
bacterial and fungal contamination was found in the chambers of their nebulisers (Jadhav et 
al., 2013).  Only one protocol in the current study used 70% alcohol for cleaning the Micro Mist 
small volume nebulisers. Hand hygiene was not evaluated or identified as part of the 
decontamination and storage protocols in the ICUs in Pretoria.  The CFF’s cleaning and 
disinfecting protocol for home nebulisers recommend that sterile water should be used for final 
rinsing after cleaning and that it should be air dried completely (O'Malley, 2009).  Two 
protocols used sterile water for rinsing after remaining fluid were thrown out without prior 
washing of the Micro Mist small volume nebulisers.  No literature could be found regarding the 
use of bioscrub for washing nebulisers which were included in two of the protocols identified in 
this study.  Bioscrub is a disinfectant scrub specifically formulated for hands and the body to 
help kill micro-organisms and prevent skin infections.  The use of bioscrub for the 
decontamination of Micro Mist small volume nebulisers has not been documented in 
international studies and could be totally ineffective as it’s made of skin sanitation (GHSdirect, 
2011). 
 
During an outbreak of Staphylococcus aureus the ICT at the Wirral Hospital NHS Trust 
developed a protocol whereby the nebulisers were only drained after each use and stored 
covered with a paper towel, following the manufacturer’s guidelines were impractical (Allen et 
al., 2005).  The ICT also decided to replace nebulisers after 24h (Allen et al., 2005). O’Malley 
(2009) found that in-hospital nebulisers used for cystic fibrosis patients can be safely used for 
24-hours and replaced without cleaning.  No Micro Mist small volume nebulisers were replaced 
according to the cardex and files at the bedsides of patients in the ICUs in Pretoria. 
 
  In two of the protocols, drying was not done before storage which is in contrast with 
manufacturer’s guidelines, specifically for Hudson RCI (SMTL, 2000).  They recommend that 
the Micro Mist small volume nebuliser must be re-assembled after cleaning and run as empty 
to remove any remaining water and store in a dry clean place.  Only in protocol one were the 
nebulisers dried and left open to the environment.  The remaining storage protocols used 
methods to cover the Micro Mist small volume nebuliser which is in contrast with the 
manufacturer’s guidelines (SMTL, 2000).  It can be assumed that the nebulisers covered and 
not dried or dried thoroughly can remain wet.  Nebulisers stored open to the environment have 
a better chance to dry completely. Storing nebulisers by using a glove was the method most 
included in the protocols (n=3) which corresponds with the method mostly used to store Micro 
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Mist small volume nebulisers in ICUs in Johannesburg (Ellis et al., 2013).  The methods of 
storage used for the Micro Mist small volume nebulisers in the ICUs in Johannesburg 
corresponded with the storage methods stated in the storage protocols of ICUs in Pretoria. 
 
5.5 THE INCIDENCE OF CONTAMINATION OF NEBULISERS AFTER USE WITHIN A 
VENTILATOR CIRCUIT 
 
In this study the incidence of contamination found in the Micro Mist small volume nebulisers in 
the ICUs in Pretoria (51.3%) corresponds with the incidence of contamination found in the 
Micro Mist small volume nebulisers in the ICUs in Johannesburg (52%) (Ellis et al., 2013).  Half 
of the Aeroneb nebulisers presented with contamination.  No previous studies could be found 
regarding the contamination of Aeroneb nebulisers.  The total level of contamination in both 
types of nebulisers in this study (50.8%) also corresponded with the contamination levels 
found in the nebulisers used in the ICUs in Johannesburg (Ellis et al., 2013).  The results 
showed that the Aeroneb nebuliser can become contaminated and therefore is not the ultimate 
solution as previously assumed by Ellis et al. (2013).  A study done by Jadhav et al. (2013) 
found that Micro Mist small volume nebulisers used in the ICU, wards and outpatient 
department presented with 47.5% bacterial contamination.  This rate is close to what was 
found in the ICUs in Pretoria and Johannesburg.  Furthermore, 75.1% of swabs taken from 
various sites presented with fungal growth which included swabs from Micro Mist small volume 
nebulisers (Jadhav et al., 2013).  Our study showed similar results whereby swabs taken from 
the Micro Mist small volume nebulisers presented with both bacterial and fungal contamination. 
Fungal (45.9%) contamination was also higher than bacterial (35.1%) contamination in the 
Micro Mist small volume nebulisers, however, in the Aeroneb nebuliser bacterial contamination 
was slightly higher than fungal contamination.  Hospital one had the least contamination and 
hospital two the most contamination.  Three out of the four hospitals showed that bacterial 
together with fungal contamination were more prevalent in both nebulisers and corresponds 
with the study done by Jadhav et al. (2013).  
 
In the mixed ICU [unit five] bacterial and fungal contamination was observed the most in both 
Micro Mist small volume and Aeroneb nebulisers, followed by the medical-surgical ICU.  
According to the INICC, the average LOS for patients in an ICU consisting of mixed conditions 
was found to be much higher than other types of ICUs.  The increased LOS in the ICU with 
mixed conditions places the patient at higher risk to develop nosocomial infections and 
possible increase in ventilator time and risk for VAP (INICC, 2010).  Both bacterial pathogens 
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and fungal pathogens (to a lesser extent) play a role in the incidence of VAP (Brink et al, 
2006).  These micro-organisms gain access to the lower respiratory tract of patients through 
various mechanisms and mainly due to the endotracheal tube which provides direct access for 
bacteria into the lower respiratory tract (Crnich, Safdar & Maki, 2005; Efrati et al., 2010) 
 
 In this study six Micro Mist small volume nebulisers (n=6) were used for more than 90 
aerosolisation sessions, which is higher than the manufacturer’s recommendations (SMLT, 
2000).  Half of those nebulisers presented with bacterial as well as fungal contamination.  The 
31 nebulisers used for less than 90 aerosolisation sessions presented with less bacterial 
contamination and higher fungal contamination.  As previously stated the fungal contamination 
found in various sites which included Hudson nebulisers in the ICU were high and could 
contribute to the increase of fungal infections in the critically ill patient (Jadhav et al., 2013). 
However, it was outside the scope of the current study to test this assumption.  
 
Bronchodilator medication was associated with the most bacterial contamination in both the 
Micro Mist small volume nebuliser and the Aeroneb nebulisers in this study.  Furthermore 
mucolytics and specifically Bisolvon were used in two Micro Mist small volume nebulisers and 
presented with zero contamination.  This corresponds with results obtained from the ICUs in 
Johannesburg and further supports Oie et al. (2013) hypothesis that preservatives in residual 
aerosol medication after usage could assist in reducing bacterial growth.   
 
 In this study there was more yeast than mould contamination in both types of nebulisers.  
Certain moulds have recently been recognised as emerging nosocomial pathogens and 
Candida spp. (yeast) causes a majority of nosocomial infections (Jadhav et al., 2013).  In the 
study done by Jadhav et al., (2013) more moulds (Aspergillus fumigatus & Aspergillus niger) 
were isolated in the chambers of Micro Mist small volume nebulisers which included nebulisers 
from the ICU.  
 
 The decontamination and storage protocol that resulted in the least fungal and bacterial 
contamination was protocol one.  This protocol consisted of rinsing nebulisers with 70% 
alcohol, drying with a paper towel and leaving them open to the environment.  Jadhav et al. 
(2013) found that the fungal and bacterial contamination rate of Micro Mist small volume 
nebulisers decreased significantly after disinfecting with 70% ethanol which could explain the 
low rate of contamination found in the current study with protocol one.  As previously stated, 
nebulisers stored open to the environment have a better chance to dry completely.  Drying is a 
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very important part of a decontamination protocol as devices left wet can result in multiplication 
of bacteria (O’ Malley, 2009).  Ellis et al. (2013) found that two dry Micro Mist small volume 
nebulisers with residual solute observed during assessment presented with no bacterial 
growth.  These two nebulisers were left connected to oxygen running at 1l/min and were 
completely dry.  The flow of oxygen could have assisted in drying the nebulisers in a shorter 
period of time (Ellis et al., 2013).  High concentrations of oxygen have also been shown to 
reduce the growth of certain bacteria (Schobert and Tielen, 2010).  Certain bacteria grow more 
prolifically in moist environments and therefore it can be assumed that nebulisers stored dry 
have a lesser chance of presenting with bacterial growth (Ellis et al., 2013).  In this study the 
oxygen flow stopped after the ventilator’s aerosolisation cycle was completed and therefore 
could not assist in drying the chambers of the Micro Mist small volume nebulisers even though 
it was still connected to the ventilator.  
 
 In this study decontamination and storage protocol two resulted in a high incidence of 
contamination (n=8; 66.7%) especially fungal contamination. In this protocol, no drying of the 
Micro Mist small volume nebuliser was done as the nebulisers were rinsed with Provac water 
and left to dry under a sterile cloth.  According to the unit manager these sterile cloths are 
replaced every week.  Similar results were found by Ellis et al. (2013) whereby Micro Mist 
small volume nebulisers that were stored under a sterile drape presented with higher 
concentrations of bacterial growth than nebulisers stored in a latex/non-sterile glove or open to 
the environment.  The dark environment created by the sterile drape could enhance the growth 
of certain bacteria as light inhibits the growth of these bacteria (Sagripanti et al., 2013).  
Protocol three resulted in the highest rate of bacterial (n=3; 60%) and fungal (n=5; 80%) 
contamination respectively.  These Micro Mist small volume nebulisers were reported to be 
stored in an acceptor/sterile bag after being washed with bioscrub and dried. During data 
collection no paper bags were identified during assessment of the twelve Micro Mist small 
volume nebulisers where protocol three was in place.  Nine of the 12 Micro Mist small volume 
nebulisers were stored in a glove, two open to the environment and one left in the ventilator 
circuit.  Therefore it can be assumed that the storage protocol for that ICU was not followed.  
Ellis et al. (2013) found that two nebulisers stored in paper bags retrieved from sterile packs 
resulted in zero contamination.  However these two nebulisers were left with 1l/min oxygen 
running through them while they were stored in these paper bags.  Although paper has a 
greater absorbency than non-sterile/latex gloves the reason for the absence of contamination 
in the light of the results found in this study could be contributed to the continuous flow of 
oxygen.  Therefore the results from the study done by Ellis et al., (2013) and from the current 
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study regarding the association of contamination with paper bags as storage method were 
inconclusive.  No evidence regarding this type on storage method could be sourced from the 
literature. 
 
 As previously stated, drying the nebuliser after decontamination is an important step in the 
cleaning protocol.  When nebulisers were dried with a paper towel the least contamination was 
found.  Nebulisers taken apart and left to dry under a sterile cloth with no prior drying resulted 
in the most fungal and bacterial contamination.  The high rate of contamination that resulted 
from method two could be due to the moist and dark environment created by the covering with 
the sterile drape as highlighted by Ellis et al. (2013).  
 
 The contamination associated with decontamination and storage protocols of each unit 
corresponded with the contamination resulted from methods of storage observed at the bed 
side. Most Micro Mist small volume nebulisers that were assessed were stored in a non-
sterile/latex glove.  As previously stated this also corresponded with the method used mainly to 
store Micro Mist small volume nebulisers in the ICUs in Johannesburg (Ellis et al., 2013).  
However the most bacterial and fungal contamination were found in the Micro Mist small 
volume nebulisers left to dry under a sterile cloth.  
 
 Most of the Micro Mist small volume nebulisers were stored wet and most of the Aeroneb 
nebulisers left in the ventilator circuit were also wet with assessment.  More bacterial and 
fungal contamination was found in wet Micro Mist small volume and Aeroneb nebulisers.  One 
dry Micro Mist small volume nebuliser presented with fungal and bacterial contamination and 
one dry Aeroneb with bacterial and two with fungal contamination.  In this study there was a 
profound difference in the contamination levels between nebulisers stored wet and nebulisers 
stored dry.  The assumption made by Ellis et al. (2013) that nebulisers that are stored dry can 
reduce the bacterial growth of certain strains is supported by the results of this study.  The 
current practice of decontamination contributed to the high rate of contamination found in Micro 
Mist small nebulisers and supports the hypothesis stated in this study. Aeroneb nebulisers 
were left in the ventilator circuit and no decontamination protocol was applied.  Therefore the 
hypothesis is rejected for this type of nebuliser. 
 
  Most of the BAPs of the Micro Mist small volume nebulisers (n=7) as well as Aeroneb (n=10) 
nebulisers presented with one bacterial species during visual assessment.  More colonies 
(CFU) were found on the BAPs sampled from wet Micro Mist small volume nebulisers than 
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from wet Aeroneb nebulisers. Interestingly, one BAP of a dry Micro Mist small volume 
nebuliser and one BAP of a dry Aeroneb nebuliser presented with one species but with more 
than 50 colonies.  Most BAPs of Micro Mist small volume nebulisers in the ICUs in 
Johannesburg presented with colonies (CFU) between one and two (Ellis et al. (2013) which 
stands in contrast with the findings found in Pretoria whereby most BAPs presented with more 
than 50 colonies.    
 
5.6 BACTERIAL MICRO-ORGANISMS IDENTIFIED IN CONTAMINATED NEBULISERS AND 
SURROUNDING AIR 
 
Ten types of organisms were identified in the samples taken from both types of nebulisers and 
their surrounding air.  The predominant organism identified in air samples and Aeroneb 
nebuliser were CoNS. Only one Micro Mist small volume nebuliser presented with CONS (n=1; 
16.7%).  Staphylococcus aureus was identified in one Aeroneb nebuliser (n=1; 14.3%) and one 
air sample (n=1; 5.2%).  Jadhav et al. (2013) identified MRSA, Methicillin-sensitive 
Staphylococcus aureus (MSSA) and CoNS in the chambers of Micro Mist small volume 
nebulisers, this included nebulisers used in the ICUs.  Staphylococcus aureus and CoNS are 
pathogens known to lead to the development of VAP (Joseph et al., 2010).  Enterococcus spp. 
were identified in two Micro Mist small volume nebulisers (n=2; 33.3%) and were also identified 
in Aeroneb nebulisers and air samples.  Enterococcus species are also a common cause of 
VAP (Joseph et al., 2010). Other species identified by Jadhav et al. (2013) included 
Pseudomonas spp., Acinetobacter spp., E. coli and Klebsiella spp. which were not identified in 
the nebulisers in this study.  Gram negative bacteria presented 68.9% of the total bacterial 
isolates and gram positive cocci 31.1% (Jadhav et al., 2013).  In the current study, gram 
positive and negative cocci were equally prevalent.  Furthermore, Stenotrophomonas spp. and 
Neisseria spp. were identified in one Micro Mist small volume nebuliser and Neisseria spp. in 
three air samples.  These micro-organisms are an unusual cause of VAP (Joseph et al., 2010).   
 
5.7 SIMILAR BACTERIAL MICRO-ORGANISMS CULTURED FROM CONTAMINATED 
NEBULISERS AND AIR SAMPLES 
 
High contamination levels were identified in air samples (n=60; 98.4%).   Fungal contamination 
was more prevalent than bacterial contamination in the surrounding air of the ICUs in Pretoria.  
In this study CoNS was the micro-organism most detected in air samples (n=8).  These 
findings correlate with the study done by Qudiesat et al. (2009) whereby CoNS was one of the 
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micro-organisms most detected in the air in a private and governmental hospital.  The other 
two micro-organisms detected in the air were Staphylococcus aureus and Micrococcus 
(Qudiesat et al., 2009).  In this study Staphylococcus aureus and Micrococcus were only 
detected in one air sample respectively.  In contrast with our study Huang et al. (2013) found 
that Pseudomona aeruginosa was the most frequent and abundant micro-organism found in air 
samples in two ICUs and showed a positive correlation of mean counts between samples taken 
from the air and surface. 
 
The micro-organism identified in the chamber of a nebuliser and its surrounding air was 
identical in two instances in the current study.  Enterococcus spp. was identified in a Micro Mist 
small volume nebuliser and its surrounding air and CoNS was identified in an Aeroneb 
nebuliser and its surrounding air.  Although identical micro-organisms were identified in both 
nebulisers and its surrounding air, it cannot be assumed that the surrounding air was the only 
contributor as results showed that different decontamination and storage methods play an 
important role in the possible contamination of Micro Mist small volume nebulisers.  
 
 The findings do not support the second hypothesis stated for the study.  Although the Aeroneb 
nebulisers were less exposed to handling and surrounding air, they still had contamination 
rates similar to the contamination rates found in the Micro Mist small volume nebulisers.  It can 
be assumed that contamination found in the Aeroneb resulted from possible contamination of 
the ventilator circuit and that the moist environment encouraged the growth of micro-
organisms.  Therefore the hypothesis was rejected as the micro-organisms found in the 
nebulisers and the surrounding air were only identical in two instances.  
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CHAPTER 6 
 
6.  CONCLUSIONS 
Two types of nebulisers used within a ventilator circuit in the ICUs in Pretoria were the Micro 
Mist small volume nebuliser and a fairly new device the Aeroneb nebuliser.  The majority of 
nebulisers used within the ICUs were Micro Mist small volume nebulisers.  All four private 
hospitals reported to have decontamination and storage protocols in place for the Micro Mist 
small volume nebuliser. The Aeroneb nebuliser is manufactured to stay in the ventilator circuit 
and therefore decontamination and storage is not applicable. 
 
This study found that both types of nebulisers presented with fungal and bacterial 
contamination. The contamination rates found in the Micro Mist small volume and Aeroneb 
nebulisers were similar when compared to the contamination rate reported for the Micro Mist 
small volume nebulisers in the ICUs of hospitals in Johannesburg. Although the ICUs in 
Pretoria had decontamination and storage protocols the incidence of contamination were the 
same in the ICUs of hospitals in Johannesburg where no decontamination and storage 
protocols were implemented.  Evaluation of staff adherence to the different protocols was not a 
specific aim of the current study as staff adherence to reported protocols may have played a 
role in contamination of nebulisers.  
 
Most of the Micro Mist small volume nebulisers were stored wet and therefore it could be 
assumed that decontamination protocols were not followed. To further bring weight to this 
assumption is that the method used to store the nebulisers as observed during assessment did 
not correspond with the storage protocol reported by the ICU on the day of audit.   Of these 
wet Micro Mist small volume nebulisers almost a third presented with bacterial contamination 
and almost half with fungal contamination. Most of the wet nebulisers presented with higher 
concentration of bacteria but only one type of species. Micro Mist small volume nebulisers that 
were stored under a sterile cloth presented with a higher percentage of fungal and bacterial 
contamination which corresponded with the results found in the Micro Mist small volume 
nebulisers the ICUs of hospitals in Johannesburg.  The nebulisers that were stored open to the 
environment and rinsed with 70% alcohol had the least bacterial growth.   
 
Air samples in this study revealed very high rates of contamination in the ICUs in Pretoria. 
Fungal contamination was more prevalent than bacterial contamination.  Bacterial and fungal 
pathogens in the air can be distributed across distances in the hospital units and come to settle 
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on surfaces or transferred to other surfaces.  Clearly nebulisers left open to the environment 
can become contaminated with pathogens in the air.  This risk increases, when nebulisers are 
not properly dried.  In this study two micro-organisms identified in the nebulisers were similar to 
the micro-organisms found in the air sample taken at the bed side where the nebuliser was 
kept. A coagulase-negative Staphylococcus sp. was identified in one Aeroneb nebuliser and its 
corresponded air sample and an Enterococcus sp. was observed in one Micro Mist small 
volume nebuliser and its corresponding air sample. Coagulase-negative Staphylococcus sp. 
was also mostly identified in air and Aeroneb nebulisers samples. 
 
This study found support that aerosolisation of medication is an important and frequent therapy 
in the treatment of patients receiving MV.  The development of more aerosol medication due to 
absorption benefits makes it necessary to develop protocols that will ensure the safety of 
aerosol therapy delivery to the critically ill patient. 
 
 6.1 LIMITATIONS OF THIS STUDY 
 No government sector hospitals were included in the study as none gave consent in the 
time period set aside for acquiring consent and data collection.  
 The ICU staff were not evaluated regarding their adherence to implementation of the 
decontamination and storage protocols in their ICUs as this was not the particular aim of 
the current study.  The rate of contamination associated with the adherence to 
decontamination and storage protocols could have indicated the difference in the incidence 
of contamination of application and number of applications of these protocols. 
 
 Pathogens identified within the respiratory system of patients where sampling were done, 
were not always documented on the cardex. Correlation of pathogens in the nebuliser and 
the patients’ respiratory system could be done.  This type of correlation could assist further 
in identifying the method by which the nebulisers could have become contaminated. 
 
 Identification of the bacterial cultures grown on the BAPs, was costly and therefore BAPs of 
air and nebuliser samples were chosen through visual inspection of the most recurrent 
colonies for identification.  Similar micro-organisms could have been found between air and 
nebuliser with the identification of more samples and could assist in identifying the role that 
environmental contamination can play in the contamination of Micro Mist small volume 
nebulisers and their method of storage. 
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6.2 RECOMMENDATIONS FOR FUTURE RESEARCH  
 The incidence of contamination of nebulisers used within a ventilator circuit and 
decontamination protocols used in the ICUs in the government sector hospitals in Pretoria 
should be investigated and the findings compared with the results found in this study and 
the study done in Johannesburg, South Africa. This can further assist in the development of 
a national decontamination and storage protocol for nebulisers that is cost effective, 
practical and evidence based. 
 
 This study and previous studies regarding contamination of nebulisers should form the 
platform for the development of evidence based decontamination and storage protocols. 
Nursing staff and physiotherapists in the ICU are the health professionals that give aerosol 
therapy on a regular basis to patients receiving MV and therefore must take the lead in the 
development of these protocols. The role that the surrounding air plays in the 
contamination of the ICU environment must be taken into account when developing these 
protocols.  
 
 Unit managers should take the responsibility to inform ICU nursing staff and 
physiotherapists regarding the decontamination and storage protocols in their units and the 
importance of adherence to these protocols.  Individual ICU staff and physiotherapists must 
aim to give aerosol therapy safely and effectively and therefore normal infection control 
activities like hand washing and gloving should be done.  Furthermore nursing staff and 
physiotherapists in the ICU must be informed regarding the potential danger of 
contaminated nebulisers and the role they can play in the development of antibiotic 
resistant VAP. 
  
 The results from this study support the development of an evidence based decontamination 
and storage protocol for jet nebulisers.  Staff adherence to such an evidence based 
decontamination and storage protocol should be evaluated to assess the feasibility of such 
protocols.  
 
 The future incidence of contamination after implementation of evidence based 
decontamination and storage protocol for jet nebulisers used within a ventilator circuit 
should be investigated. 
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 The incidence of contamination of Micro Mist small volume nebulisers in the High Care 
Units and general wards, in a South African context, is unknown. The existence of 
decontamination and storage protocols in these wards is also unknown.  Patients who are 
discharged from the ICU to other units continue to use the same nebulisers and therefore 
investigation into the level of contamination of such nebulisers should be done.  
 
 The rate of contamination of Micro Mist small volume nebuliser with the use of the Valved 
Neb Tee (tee connector) is unknown.  The Valved Neb Tee that connects the Micro Mist 
small volume nebuliser to the ventilator circuit is manufactured to be left in the ventilator 
circuit.  When the Micro Mist small volume nebuliser is removed from the Valved Neb Tee, 
the valve seals the opening, preventing the circuit from being exposed to the surrounding 
air. Less handling of the circuit is required which will promote the time to spend applying 
decontamination protocols. 
 
 The application of other single-patient use respiratory devices with regards to 
contamination and storage e.g. Intermitted Positive Pressure Breath (IPPB) circuits used in 
IPPB machines could be investigated. 
 
 The indoor quality of air must be investigated to identify the possible risks associated with 
airborne pathogens in the healthcare setting and especially in the ICUs where a critically ill 
patient is more susceptible to infections.  
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 INFORMATION LEAFLET:  HOSPITAL MANAGER/CEO/INFECTION CONTROL MANAGER 
  
CONTAMINATION AND CURRENT PRACTICE IN DECONTAMINATION OF NEBULISERS IN 
VENTILATED PATIENTS 
 
I, Mrs L van Heerden, am a registered postgraduate student in the physiotherapy department of the 
University of the Witwatersrand and am currently doing a study on jet nebuliser decontamination 
practices in ventilated patients. This study will assist further research into evidence-based, cost-
effective and practical nebuliser decontamination protocols. Incorrect nebuliser cleaning, storage and 
usage may increase the risk of patients on mechanical ventilation developing ventilator-associated 
pneumonia. 
 
1. Introduction 
Your institution is invited to consider participating in this research study, which is entirely 
voluntary. Before agreeing to participate, it is important that you read and understand the 
following explanation of the purpose of the survey, the survey procedures, benefits and risks, 
as well as your right to withdraw your institution from the survey at any time. If you have any 
questions, do not hesitate to ask me. 
 
You should not agree for your institution to take part unless you are satisfied about all the 
procedures involved. If you decide that your institution can take part in this survey, you will be 
asked to sign this document to confirm that you understand the survey. You will be given a 
copy to keep for your own records. 
 
2.  Purpose of the Study 
 The purpose of this survey is to determine nebuliser contamination rate and the current 
practice in decontamination of jet nebulisers in intensive care units (ICUs) in Pretoria. 
Secondly to identify the micro-organisms that contaminate nebulisers used and the air 
around the beds of patients who received nebulisation in the ICU.  
 
3.  Length of the Study and Number of Participants 
 Sixteen hospitals in Pretoria have been selected to participate in this survey. 
 Data collection will occur in the period July - September 2012. 
 There will only be one site visit at your institution. 
4. Procedures 
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 If you agree that your institution may take part in this survey, the unit manager of the ICU 
will be asked questions regarding the demographics of the ICU and the nebuliser 
decontamination protocol that is currently in place. This will be followed by an audit of the 
unit to identify nebulisers currently used in ventilator circuits. The nebulisers will be 
examined by me as they have been stored.  Each nebuliser will be swabbed according to 
the protocol for the study.   Staff activity in the unit will not be disturbed.  
 Air samples at the bedside of patients who had received nebuliser therapy will be taken 
thereafter  
 There will be no record kept of which staff member is responsible for which nebuliser. 
 
5.  Risks 
 While every effort has been made to ensure limitation of the publication of the names of the 
hospitals who participated in the survey, the names will only be published in the final 
research report that will be submitted for examination to the University of the 
Witwatersrand. However, there will be no link made between the names of the hospitals 
and the results obtained from the unit. 
 
6. Benefits 
 The potential benefit derived from your institution’s participation in this survey is that 
knowledge will be obtained regarding possible current nebuliser contamination and air 
contamination around the patient’s bedside.  The absence or presence of current nebuliser 
decontamination protocols will also be identified. 
 Based on this information the survey will provide a basis for future research into the 
implementation of evidence based decontamination protocols that are cost effective and 
practical within the SA ICU context.  
 
7.  Financial Arrangements 
 There will be no financial re-imbursement for participation in this survey. 
 
8.  Ethics Approval 
 This research protocol has been submitted to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been granted by that 
committee to proceed with the study. 
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 If you want any information regarding your rights as a research participant, or have any 
complaints regarding this research study, you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee, established to help protect the rights of 
research participants at (011) 717 2229.  
 The survey has been structured in accordance with the Declaration of Helsinki (last 
updated: October 2000), which deals with the recommendations guiding doctors in 
biomedical research involving human participants. A copy may be obtained from me should 
you wish to review it. 
 
9.  Confidentiality 
 All information obtained during the course of this survey, including hospital names, 
personnel data and research data will be kept strictly confidential. Data that may be 
reported in scientific journals will not include any information that identifies you or your 
hospital as a participant in this survey. The names of hospitals that have participated in the 
study will be stored in a general list, and there will be no link with the data collected. 
 The information might also be inspected by the University of the Witwatersrand, HREC).  
 These records will be utilised by them only in connection with carrying out their obligations 
relating to this survey. 
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APPENDIX 3 
 INFORMED CONSENT: HOSPITAL MANAGER/CEO/INFECTION CONTROL MANAGER 
 
CONTAMINATION AND CURRENT PRACTICE IN DECONTAMINATION OF NEBULISERS IN 
VENTILATED PATIENTS 
 
 I hereby confirm that I have been informed by the researcher, Lizl van Heerden, about the nature, 
conduct, benefits and risks of the survey titled: Nebuliser contamination and current practice in 
decontamination of nebulisers in ventilated patients, Pretoria, South Africa. 
 
 I have also received, read and understood the above-written information regarding the survey. 
 I am aware that the results of the study, including personal and professional details will be 
anonymously processed into a study report. 
 I may, at any stage, without prejudice, withdraw my consent for my institution’s participation in the 
study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself, in the 
capacity of Hospital Manager/CEO/Infection Control Manager to allow my institution to participate 
in the study. 
 
HOSPITAL MANAGER/CEO/INFECTION CONTROL MANAGER 
 
 
_____________________________________________________________________ 
Printed Name              Signature    Date and Time 
 
I, Lizl van Heerden, herewith confirm that the above participant has been fully informed about the 
nature, conduct and risks of the above study. 
 
RESEARCHER: 
 
 
______________________________________________________________________ 
Printed Name     Signature    Date and Time 
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APPENDIX 4 
 INFORMATION LEAFLET:  UNIT MANAGER  
 
Dear ICU Unit Manager 
 
Your ICU has been selected to participate in the study described below. Consent for the study has 
been obtained from the Hospital Manager/CEO/Infection Control Manager of the hospital. 
 
Study Title: Contamination and current practice in decontamination of nebulisers in ventilated 
patients. 
 
Investigators: Mrs Lizl van Heerden 
 
Institution: University of the Witwatersrand 
 
1.  Purpose of the study:  
The purpose of this survey is to determine nebuliser contamination rate and the current 
practice in decontamination of jet nebulisers in intensive care units (ICUs) in Pretoria. Secondly 
to identify the micro-organisms that contaminates nebulisers used and air around the beds of 
patients who received nebulisation in the ICU.  
 
2.  Length of the study and number of participants: 
 Sixteen hospitals in Pretoria have been selected to participate in this survey. 
 Data collection will occur in July 2012 – September 2012. 
 There will only be one site visit to your ICU. 
 
3.  Procedures: 
 The unit manager, CEO/Hospital manager and infection control manager have given 
consent for this survey. You will not be asked any personal information. You will be asked 
questions regarding the demographics of your ICU and your nebuliser decontamination 
protocol in your capacity as unit manager. This will be followed by an audit of the unit. The 
nebulisers will be examined as they have been stored. Each nebuliser will be swabbed 
according to the protocol for the study.    Staff activity in the unit will not be disturbed. 
 Air samples at the bedside of patients who had received nebuliser therapy will be taken 
thereafter  
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 There will be no record kept of which staff member is responsible for which nebuliser. 
 The only information that will be obtained from the patient’s ICU nursing chart is that 
relating to nebuliser use as stipulated in Appendix 1 section B. No additional information 
will be obtained from patient records. 
 
4.  Risks: 
 While every effort has been made to ensure limitation of the publication of the names of the 
hospitals who participated in the survey, the names will only be published in the final 
research report that will be submitted for examination to the university. However, there will 
be no link made between the names of the hospitals and the results obtained from the audit 
of the unit. 
 
5.  Benefits: 
 The potential benefit derived from your ICU’s participation in this survey is that knowledge 
will be obtained regarding possible current nebuliser contamination and air contamination 
around the patient’s bedside.  The absence or presence of current nebuliser 
decontamination protocols will also be identified. 
 Based on this information the survey will provide a basis for future research into the 
implementation of evidence based decontamination protocols that are cost effective and 
practical within the SA ICU context.  
 
6.  Financial arrangements: 
 There will be no financial re-imbursement for participation in this survey. 
 
7.  Ethical approval: 
 This survey protocol has been submitted to the University of the Witwatersrand, Human 
Research Ethics Committee (HREC) and written approval has been granted by that 
committee. 
  If you want any information regarding your rights as a research participant, or have any 
complaints regarding this research study, you may contact Prof. Cleaton-Jones, 
Chairperson of the University of the Witwatersrand, Human Research Ethics Committee 
(HREC), which is an independent committee, established to help protect the rights of 
research participants at (011) 717 2229.  
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 The survey has been structured in accordance with the Declaration of Helsinki (last 
updated: October 2000), which deals with the recommendations guiding doctors in 
biomedical research involving human participants. A copy may be obtained from me should 
you wish to review it. 
 
8.  Confidentiality 
 All information obtained during the course of this survey, including hospital names, 
personnel data and research data will be kept strictly confidential. Data that may be 
reported in scientific journals will not include any information that identifies you or your 
hospital as a participant in this survey. 
 The information might also be inspected by the University of the Witwatersrand, Human 
Research Ethics Committee HREC. 
 These records will be utilised by them only in connection with carrying out their obligations 
relating to this survey. 
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APPENDIX 5 
 INFORMED CONSENT: UNIT MANAGER 
 
CONTAMINATION AND CURRENT PRACTICE IN DECONTAMINATION OF NEBULISERS IN 
VENTILATED PATIENTS 
 
 I hereby confirm that I have been informed by the researcher, Lizl van Heerden, about the nature, 
conduct, benefits and risks of the survey titled: Nebuliser contamination and current practice in 
decontamination of nebulisers in ventilated patients, Pretoria, South Africa. 
 
 I have also received, read and understood the above-written information regarding the survey. 
 I understand that only information pertaining to nebuliser use will be obtained from the ICU charts. 
 I am aware that the results of the study, including personal and professional details will be 
anonymously processed into a study report. 
 I may, at any stage, without prejudice, withdraw my consent for my ICU’s participation in the study. 
 I have had sufficient opportunity to ask questions and (of my own free will) declare myself, in the 
capacity of the unit manager to allow my ICU to participate in the study. 
 
 
 UNIT MANAGER 
 
 
_____________________________________________________________________ 
Printed Name              Signature    Date and Time 
 
I, Lizl van Heerden, herewith confirm that the above participant has been fully informed about the 
nature, conduct and risks of the above study. 
 
RESEARCHER: 
 
 
______________________________________________________________________ 
Printed Name     Signature    Date and Time 
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APPENDIX 6 
SECTION A 
 UNIT AUDIT TOOL: CURRENT PRACTICE IN DECONTAMINATION OF NEBULISERS IN 
VENTILATED PATIENTS, PRETORIA, SOUTH AFRICA          
                                       
Hospital code: _____________________________________________________________________ 
Number of beds in unit: ______________________________________________________________ 
Number of patients on a ventilator: _____________________________________________________ 
Number of ventilated patients receiving nebulisation: _______________________________________ 
What kind of ICU: Cardio____, Medical____, Surgical____. Trauma____, Neuro____, Mixed_______ 
 
Nurses: 
Number of staff on duty: _____________________________________________________________ 
Number of permanent staff: __________________________________________________________  
Number of agency staff: _____________________________________________________________ 
Physiotherapists: 
Number of staff on duty: _____________________________________________________________ 
Number of permanent staff: __________________________________________________________ 
Number of locum staff: ______________________________________________________________ 
 
 
Is there a ventilator nebuliser decontamination protocol for this unit? YES NO 
Nebuliser discarded after each use?      YES NO 
Nebuliser rinsed with a solution?      YES  NO 
Solution?.........…………………………………………………………………………………………………..…
.      
Nebuliser dried?        YES NO 
Material used to dry nebuliser?………………………………………….………………………………………. 
 
Nebuliser stored: 
Glove          YES     NO 
Sterile cloth         YES  NO 
Open to the environment        YES NO 
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Paper bag          YES NO 
With residual solute         YES NO 
Attached to oxygen tubing        YES  NO 
Nebuliser autoclaved         YES NO 
If yes, method used: ……………………………………………………………………………………………… 
Other observations made:  
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………… 
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APPENDIX 6 
SECTION B 
 NEBULISER ASSESSMENT FORM 
 
Nebuliser number:__________________________________________________________________ 
Hospital number:___________________________________________________________________ 
Manufacturer:______________________________________________________________________ 
Single use:____________Single patient use:________________ Autoclave:____________________ 
 
 
Prescribed medication:_______________________________________________________________ 
Date when nebulisation started__________________________   /____hourly___________________ 
Time of last nebulisation:_________________________________________________ 
Time of assessment:_____________________________________________________ 
Days on Ventilation:______________________________________________________ 
 
Environment at bedside 
Windows         YES NO 
Natural light         YES NO 
Artificial light         YES NO 
Cubicle isolated        YES NO 
Blinds          YES NO 
Nebuliser discarded after use       YES NO 
Nebuliser dry          YES NO  
If yes, is there dry solute in the chamber?      YES NO 
If no, appearance of solution        Clear  Opaque 
Nebuliser stored: 
Glove           YES NO 
Sterile cloth          YES NO 
Open to the environment        YES NO 
Paper bag         YES NO 
Removed from oxygen tubing       YES NO 
Nebuliser sent to be autoclaved       YES NO 
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Other observations made 
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
……………………………………………… 
 
Air sample at bedside  
Persons at bedside:..................................................................................................................... 
Sample one:  Time.............. 
Sample two:   Time.............. 
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APPENDIX 7 
 Turn-it-In Plagiarism Scan 
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